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Abstract
Pectin (E 440i) and amidated pectin (E 440ii) were re-evaluated in 2017 by the former EFSA Panel on
Food Additives and Nutrient sources added to Food (ANS). As a follow-up to this assessment, the
Panel on Food Additives and Flavourings (FAF) was requested to assess the safety of pectins (E 440i,ii)
for their uses as food additives in food for infants below 16 weeks of age. In addition, the FAF
Panel was requested to address the issues already identified during the re-evaluation of the same food
additive. The process involved the publication of a call for data to allow the interested business
operators to provide the requested information to complete the risk assessment. Based on the
information submitted in response to the call for data, the FAF Panel considered it feasible to amend
the current specifications, in particular for the toxic elements arsenic, lead, cadmium, mercury and for
sulfur dioxide and to introduce new specifications for aluminium and microbiological criteria. Studies on
neonatal piglets, clinical studies and post-marketing data were made available during the call for data.
Due to the low internal validity of the clinical studies, the Panel concluded that a reference point could
not be derived from them, but the results of the adequate piglet study could serve to derive a
reference point. When calculating the margin of safety for pectins exposure, this was below 1 for some
scenarios. At the maximum permitted levels (MPLs), an internal methanol dose would be produced
that could lead to adverse health effects in infants below 16 weeks of age. The FAF
Panel recommended a reduction of the MPL of pectin (E 440i) and amidated pectin (E 440ii) in food
categories 13.1.5.1 and 13.1.5.2, in order to reduce the exposure to both the additives themselves
and to methanol.
© 2021 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.





Panel members: Maged Younes, Gabriele Aquilina, Laurence Castle, Karl-Heinz Engel, Paul Fowler,
Maria Jose Frutos Fernandez, Peter F€urst, Ursula Gundert-Remy, Rainer G€urtler, Trine Husøy, Melania
Manco, Wim Mennes, Peter Moldeus, Sabina Passamonti, Romina Shah, Ine Waalkens-Berendsen,
Detlef W€olfle and Matthew Wright.
Note: The full opinion will be published in accordance with Article 8 of Regulation (EU) No 257/2010
once the decision on confidentiality will be received from the European Commission.
Suggested citation: EFSA FAF Panel (EFSA Panel on Food Additives and Flavourings), Younes M,
Aquilina G, Castle L, Engel K-H, Fowler P, Frutos Fernandez MJ, F€urst P, G€urtler R, Husøy T, Manco M,
Mennes W, Moldeus P, Passamonti S, Shah R, Waalkens-Berendsen I, W€olfle D, Wright M, Dusemund B,
Mortensen A, Turck D, Barmaz S, Tard A, Vianello G and Gundert-Remy U, 2021. Opinion on the
re-evaluation of pectin (E 440i) and amidated pectin (E 440ii) as food additives in foods for infants
below 16 weeks of age and follow-up of their re-evaluation as food additives for uses in foods for all
population groups. EFSA Journal 2021;19(1):6387, 57 pp. https://doi.org/10.2903/j.efsa.2021.6387
ISSN: 1831-4732
© 2021 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited and no
modifications or adaptations are made.
The EFSA Journal is a publication of the European Food
Safety Authority, an agency of the European Union.
Opinion on the re-evaluation of pectin (E 440i) and amidated pectin (E 440ii) as food additives
in foods for infants below 16 weeks of age and follow-up of their re-evaluation as food
additives for uses in foods for all population groups
www.efsa.europa.eu/efsajournal 2 EFSA Journal 2021;19(1):6387
Summary
In accordance with Regulation (EU) No 257/2010, the European Food Safety Authority (EFSA) is
currently re-evaluating the safety of food additives already permitted in the Union before 20 January
2009 and issuing scientific opinions on their safety when used in food as per Annexes II and III to
Regulation (EC) No 1333/2008. The risk assessment approach followed in the re-evaluation has not
covered the use of food additives in food for infants below 12 weeks of age. Additionally, while re-
evaluating the safety of food additives referred to above, EFSA identified some concerns, namely (1)
data gaps that have triggered recommendations in the published scientific opinions; and/or (2) data
gaps that have increased uncertainties linked to the risk assessment and/or which prevented the
Panel from concluding on some aspects of it.
On 31 May 2017, EFSA published a guidance on the risk assessment of substances present in food
intended for infants below 16 weeks of age, thus enabling EFSA to assess the safety of food additive
used in food for infants below this age. The age up to 16 weeks was selected in the guidance because
infants are exposed to formula feeding until this age as the only source of food since complementary
feeding is not supposed to be introduced before.
As follow-up of the above, this Opinion addresses the data gaps previously identified during the re-
evaluation of pectin (E 440i) and amidated pectin (E 440ii) including the risk assessment of pectin
(E 440i) and amidated pectin (E 440ii) for the use as food additive in food according to food category
(FC) 13.1.5.1 (dietary foods for infants for special medical purposes and special formulae for infants)
and FC 13.1.5.2 (dietary foods for babies and young children for special medical purposes as defined
in Directive 1999/21/EC) in infants above 16 weeks of age and young children up to 3 years and the
safety in the special subpopulation of infants below 16 weeks of age. The process followed involved
the publication of a dedicated call for data allowing all interested parties to provide the requested
information for completing the assessment and to confirm that the additive is present in food
categories 13.1.5.1 (Dietary foods for infants for special medical purposes and special formulae for
infants). The data submitted in response to the call for data on pectin (E 440i) and amidated pectin
(E 440ii) comprised technical information and biological and toxicological data i.e. studies on neonatal
animals, literature studies including clinical studies on gastrointestinal effects in adults and post-
marketing surveillance reports.
According to Commission Regulation (EU) No 231/2012, pectin (E 440i) consists mainly of the
partial methyl esters of polygalacturonic acid and their ammonium, sodium, potassium and calcium
salts. It is obtained by extraction in an aqueous medium of strains of appropriate edible plant
material, usually citrus fruits or apples. Amidated pectin (E 440ii) consists mainly of the partial methyl
esters and amides of polygalacturonic acid and their ammonium, sodium, potassium and calcium salts.
It is obtained by extraction in an aqueous medium of appropriate strains of edible plant material,
usually citrus fruits or apples and treatment with ammonia under alkaline conditions. Specifications for
pectin (E 440i) and amidated pectin (E 440ii) have been defined in Commission Regulation (EU) No
231/2012.
The Panel considered feasible to amend the EU specifications based on the information submitted
in response to the call for data. This refers to lowering existing limits for toxic elements (arsenic, lead,
cadmium, mercury) and sulfur dioxide and to include limits for aluminium and microbiological criteria
(including Cronobacter (Enterobacter) sakazakii) for the food additive.
Dietary exposure to pectins (E 440) from their uses as food additives was assessed based on (1)
MPLs set out in the EU legislation (defined as the regulatory maximum level exposure assessment
scenario) and (2) the reported use levels (defined as the refined exposure assessment scenario).
For infants below 16 weeks of age, both scenarios are based on the recommended consumption
levels from the relevant EFSA Scientific Committee guidance which recommends values of 200 and 260
mL formula/kg body weight (bw) per day as conservative mean and high-level consumption values for
14- to 27-day-old infants. For infants below 16 weeks of age consuming food for special medical
purpose (FC 13.1.5.1), mean exposure to pectins (E 440) in the regulatory maximum level exposure
assessment scenario was estimated at 2,000 mg/kg bw per day while at the high level was estimated
at 2,600 mg kg bw per day. Using the maximum level reported by industry, exposure estimates for
pectins (E 440) were estimated at 834 mg/kg bw per day at the mean and at 1,084 mg/kg bw per day
at the high level. For the scenario using the mean of the reported use levels from industry, exposure
estimates for pectins (E 440) were of 693 mg/kg bw per day at the mean and 901 mg/kg bw per day
at the high level of consumption. For infants above 16 weeks of age and toddlers consumers of foods
for special medical purposes, mean dietary exposure to pectins (E 440) ranged from 9 mg/kg bw per
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day in toddlers to 434 mg/kg bw per day in infants above 16 weeks of age. At the high level (95th
percentile), dietary exposure to pectins (E 440) ranged from 30 mg/kg bw per day up to 1,263 mg/kg
bw per day in infants above 16 weeks of age.
No new data were provided concerning ADME, acute toxicity, short-term and subchronic toxicity,
genotoxicity, chronic toxicity and carcinogenicity and reproductive and developmental toxicity.
Two 21-day feeding studies in neonatal piglets available to the Panel were allocated to tier 1 in the
risk of bias (RoB) assessment (low risk of bias). In these studies, the piglets received a milk replacer
formula containing pectins in concentrations of 0, 0.5, 3 and 10 g/L or 0, 2 and 10 g/L, respectively.
No adverse effects on body weight, feed intake clinical parameters (haematology, clinical chemistry
and urinalysis) and post-mortem organ weights and gross and histopathology up to 3 g pectins/L in
the first study and on body weight and feed intake at 2 g pectins/L in the second study were
observed. These concentrations corresponded to 1,069 and 704 mg pectins/kg bw per day,
respectively. The data were not suitable to perform benchmark dose modelling. Due to the dose
spacing and the broader selection of toxicologically relevant endpoints, the Panel considered that the
no observed adverse effect level (NOAEL) for pectin was 1,069 mg /kg bw per day.
Seven publications of clinical studies were submitted by the interested business operator. The
composition of the tested formulas was not available neither from the publications nor provided from
the interested business operators. Only the content of pectins was provided and in addition the
information on the presence of other thickeners in the formulas. The Panel noted that none of the
formulas did contain pectins as the only source for thickening but additional locust bean gum (five
formulas) or xanthan gum (three formulas). The clinical studies were assessed with respect to their
RoB and all were allocated to tier 3 (high risk of bias). The Panel notes the methodological limitations
of the clinical studies, in particular the absence of randomisation and the fact that in none of the
studies pectin and amidated pectins (E 440i, E 440ii) were the only thickeners used so that the results
cannot be attributed to these food additives. Furthermore, most of the studies are studies without a
control group precluding any conclusions to be drawn. Because of the limitations the Panel considers
that the studies cannot support the assessment of the safety of pectin and amidated pectin (E 440i,
E 440ii). Furthermore, publications with pectin-derived acidic oligosaccharides were reviewed by the
Panel and assigned a tier 3 (high risk of bias). These studies did not provide any relevant information
for RA of pectins as a food additive.
The Panel considered that the post-marketing surveillance data do not show specific alerts except
for the very rare symptoms of ‘allergic reaction/intolerance’.
The Panel decided to base its safety assessment on the MOS calculated for the different age groups
and different scenarios. Due to the low internal validity of the clinical studies, the Panel concluded that
a reference point could not be derived from them, but the results of the adequate piglet study could
serve to derive a reference point. When calculating the MOS for pectins exposure, this was below 1 for
some scenarios. The Panel concluded that an MOS below 1 is too low.
According to the literature, consumption of pectin (75% methylated) induced a significant increase
in methanol in the breath and, by inference, in the blood. At the dose of 10 g, the lowest amount of
methanol released is 400 mg per adult person (5.7 mg/kg bw). The extrapolation of these results to
the assessment of exposure via foods for infants below 16 weeks of age under FC 13.1.5.1 would
result in an exposure of 79.7 mg/kg bw per day (for pectin exposure of 2,000 mg/kg bw per day) and
of 103.6 mg/kg bw per day (for pectin exposure of 2,600 mg/kg bw per day) towards methanol
released from pectin in infants below 16 weeks of age. Although the flora of gastrointestinal tract is
not fully comparable in the first days of life to that of the adult, after birth the microbiome of the
newborn infants becomes similar to that of the mother. The interested business operators reported a
degree of methylation between 50% and 90% for pectin (E 440i) and between 20% and 50% for
amidated pectin (E 440ii). When performing the calculation with a degree of methylation of 90%
(instead of 75%), the resulting values would be 15% higher (91.6 mg/kg bw per day and 119.4 mg/kg
bw per day). This exposure could lead to adverse health effects. Blindness in human may occur, as
reported, at doses as low as 214 mg/kg bw as a single acute dose and 260 mg/kg by the ECHA
Committee for risk assessment in 2015. Metabolic acidosis is another health impairment which
becomes relevant at doses between 100 and 150 mg/kg bw per day. A derived no effects level (DNEL)
of 88 mg/kg bw (based on methanol ocular toxicity, i.e. blindness in humans) was set by the ECHA
Committee for risk assessment (RAC) in 2015 for adults. When the maximum use level provided by
industry are considered, the exposure to methanol via foods for infants below 16 weeks of age under
FC 13.1.5.1 would result in an exposure of 43.2 mg/kg bw per day (for pectin exposure of 1,084 mg/
kg bw per day, 95th percentile) towards methanol released from pectin. The Panel considered this as a
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conservative approach also noting that the intake of pectins will not be as a single bolus dose but in
divided doses over the day.
On the basis of the above, the Panel recommended the European Commission to consider revising
the current EU specifications and to consider lowering the MPL of pectin (E 440i) and amidated pectin
(E 440ii) in FCs 13.1.5.1 and 13.1.5.2, in order to reduce the exposure to both the additives
themselves and to methanol.
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1. Introduction
The present opinion deals with:
• the risk assessment of pectin (E 440i) and amidated pectin (E 440ii) in food for infants below
16 weeks of age in the food categories (FC) 13.1.5.1 (Dietary foods for infants for special
medical purposes and special formulae for infants) according to Annex II to the Regulation
(EC) No 1333/20081 on food additives.
• the follow-up on issues that have been expressed in the conclusions and recommendations of
the Scientific Opinion on the re-evaluation of pectin (E 440i) and amidated pectin (E 440ii) as
a food additive (EFSA ANS Panel, 2017) including the risk assessment of pectin (E 440i) and
amidated pectin (E 440ii) for the use as food additive in food according to FC 13.1.5.1
(dietary foods for babies and young children for special medical purposes as defined in
Directive 1999/21/EC) and FC 13.1.5.2 (dietary foods for babies and young children for special
medical purposes as defined in Directive 1999/21/EC) in infants above 16 weeks of age and
young children up to 3 years.
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
The composition of food intended for infants and young children, as defined by Regulation (EU) No
609/20132, is regulated at EU level and such rules include requirements concerning the use of
substances as food additives.
The use of food additives is regulated by Regulation (EC) No 1333/2008 on food additives. Only
food additives that are included in the Union list, in particular in Annex II and III to that Regulation,
may be placed on the market and used in food under the conditions of use specified therein.
In accordance with Regulation (EU) No 257/20103, EFSA is currently re-evaluating the safety of
food additives already permitted in the Union before 20 January 2009 and issuing scientific opinions on
their safety when used in food as per Annexes II and III to Regulation (EC) No 1333/2008. However,
the risk assessment approach followed until now has not covered the use of food additives in food for
infants below 12 weeks of age. Consequently, EFSA published several scientific opinions on the re-
evaluation of the safety of food additives permitted in food category 13.1 but not addressing their use
in food for infants below 12 weeks of age.
In addition, in these opinions EFSA identified some concerns, namely (1) Data gaps that have
triggered recommendations in the (to be) published scientific opinions, and/or; (2) Data gaps that
have increased uncertainties linked to the risk assessment and/or which prevented the EFSA from
concluding on some aspects of it.
On 31 May 2017, EFSA published a guidance document (EFSA Scientific Committee, 2017) on the
risk assessment of substances present in food intended for infants below 16 weeks of age, thus
enabling EFSA to assess the safety of food additives used in food for infants below 12 weeks of age.4
Now EFSA is expected to launch dedicated calls for data to be able to perform such risk assessments.
The EC considers it is more effective that EFSA, in the context of these dedicated calls for data,
also addresses all the issues and data gaps already identified in the relevant (to be) published scientific
opinions on the re-evaluation of the safety of food additives permitted in food category 13.1.
In accordance with the current EC approach for the follow-up of EFSA’s scientific opinions on the
re-evaluation of the safety of permitted food additives for which some concerns have been identified, a
specific call for data would be published by the EC on DG SANTE’s website5 on food additives and
additional (missing) information would then be provided by interested business operators to the EC.
1 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008, p. 16–33.
2 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009. OJ L 181,
29.6.2013, p. 35–56.
3 Commission Regulation (EU) No 257/2010 of 25 March 2010 setting up a program for the re-evaluation of approved food
additives in accordance with Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives.
OJ L 80, 26.3.2010, p. 19–27.
4 See Section 1.1.3.
5 https://ec.europa.eu/food/safety/food_improvement_agents/additives/re-evaluation_en
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However, for those scientific opinions on the re-evaluation of the safety of permitted food additives
in food category 13.1 for which the risk assessment does not address their uses in food for infants
below 12 weeks of age and for which some concerns have been identified by EFSA, the EC considers
that for the sake of efficiency it would be appropriate to streamline the approach as described above.
Therefore, the EC requests EFSA to address all the issues and data gaps already identified in the
relevant published scientific opinions of those food additives (or groups of additives that can be
addressed simultaneously) as part of the upcoming work on the safety assessment of food additives
uses in food for infants below 12 weeks of age.
This follow-up aims at completing the re-evaluation of the food additives in question for all food
categories, and includes calls for data covering the actual use and usage levels of food additives in
food for both infants below 12 or 16 weeks of age as well as for older infants, young children and
other groups of the population for which EFSA has already finalised its assessment.
The future evaluations of EFSA should systematically address the safety of use of food additives for
all age groups, including the infants below 12 or 16 weeks of age.
1.1.2. Terms of Reference
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20026, and as part of EFSA’s work in
completing its risk assessments concerning the use of food additives in food for infants below 12
weeks of age5, covered by the re-evaluation programme and its terms of reference, the European
Commission requests the European Food Safety Authority to address all the data gaps specified in the
recommendations made in this scientific opinions on the re-evaluation of the safety of food additives
permitted in food category 13.1 (food for infants and young children) of annex II to Regulation (EC)
No 1333/2008.
1.1.3. Interpretation of Terms of reference
Before the publication of the EFSA Scientific Committee Guidance on the risk assessment of
substances present in food intended for infants below 16 weeks of age (EFSA Scientific Committee,
2017), EFSA has taken 12 weeks as a cut off age for the applicability of the safety assessment.
However, according to EFSA Scientific Committee (2017), the assessment will include infants up to 16
weeks of age because they are exposed to formula feeding until this age as the only source of food
since complementary feeding is not supposed to be introduced before this age (see EFSA Scientific
Committee, 2017).
This assessment refers exclusively to the uses of pectin (E 440i) and amidated pectin (E 440ii) as
food additives in food, including food supplements, and does not include a safety assessment of other
uses of pectins.
1.2. Previous evaluations of pectin (E 440i) and amidated pectin
(E 440ii) for use in foods for infants
The Scientific Committee on Food (SCF) in 1978 (SCF, 1978) endorsed the acceptable daily intake
(ADI) ‘not specified’ already established by JECFA (1974) for non-amidated pectins.
In JECFA (1981), assessed additional long-term feeding studies in rats, as well as multi-generation
studies, showing no toxicological differences between pectins and amidated pectins. This evaluation
was endorsed by the SCF (1985) who concluded that the database was sufficient, and established a
group ADI ‘not specified’ for non-amidated and amidated pectin.
In view of limited information on their potential effects in infants, the SCF (2003) recommended
that pectins should not be used in infant formulae and follow-on formulae. The SCF had no objections
against the continued use of pectins up to a maximum level of 10 g/L in dietary foods for special
medical purposes for infants to be used under medical supervision.
In 2014, JECFA evaluated the safety of non-amidated pectin for uses in infant formula and formula
for special medical purposes intended for infants (JECFA, 2015) and stated that ‘the Committee was
made aware that a further pectin product is available on the market. This product, known as pectin-
derived acidic oligosaccharides (pAOS), is produced by enzymatic hydrolysis of pectin. pAOS has not
6 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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been evaluated by the Committee and is not covered by the existing specifications for pectins.’ On the
basis of the observed decreased food intake and body weight gain in a neonatal pig study, JECFA also
concluded that the use of non-amidated pectin in infant formulae at the maximum proposed use levels
(0.5%) is of concern.
In an updated safety evaluation (JECFA, 2016a, 2017), JECFA calculated the margins of exposure
(MOE) for the use of pectin in infant formula at a maximum proposed use level of 0.2% using as
reference point the no-observed-effect level (NOAEL) of 1,049 mg/kg bw per day identified from a
neonatal study in piglets. The obtained margins of exposure for average and high consumption were
2.9 and 2.4, respectively. Overall, on the basis of a number of considerations (low toxicity of pectin,
NOAEL derived from a relevant study in neonatal piglets, relation of adverse effects in piglet study to
viscosity at the concentration of 1%, support of clinical studies for tolerance of infants to pectin up to
the concentration of 0.2% and conservative exposure estimates), the Committee concluded that the
MOE indicate a low risk for the health of infants aged 0–12 weeks. JECFA further stated that ‘there is
variability in medical conditions among infants requiring formula for special medical purposes and that
these infants would be normally under medical supervision’.
In its evaluation, the Nordic Council of Ministers (TemaNord, 2002) stated that pectin has been a
natural component of human diet throughout evolution and there is no indication of toxic effects
induced by pectin or amidated pectin.
The EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) addressed the scientific
substantiation of health claims in relation to pectins and reduction of post-prandial glycaemic
responses, maintenance of normal blood cholesterol concentrations and increase in satiety leading to a
reduction in energy intake (EFSA NDA Panel, 2010). A cause and effect relationship between the
consumption of pectins and a reduction of post-prandial glycaemic responses and maintenance of
normal blood cholesterol concentrations was established.
1.3. Summary of the previous EFSA re-evaluation of pectin (E 440i) and
amidated pectin (E 440ii) for uses in food for all population groups
except for infants below 12 weeks of age7
Under the frame of Regulation (EC) No 257/2010, the EFSA Panel on Food Additives and Nutrient
Sources added to Food (ANS) has re-evaluated the safety of pectin (E 440i) and amidated pectin
(E 440ii) when used as a food additive (EFSA ANS Panel, 2017).
In its scientific opinion, the ANS Panel reviewed available technical, biological and toxicological data
on of pectin (E 440i) and amidated pectin (E 440ii).
The ANS Panel concluded that pectin and amidated pectin are not absorbed intact, but extensively
fermented by intestinal microbiota in animals and humans. Although the available data were limited,
the ANS Panel concluded that there was no indication of genotoxicity for pectin and amidated pectin.
In a chronic toxicity study in rats at levels up to 5,000 mg pectin/kg bw per day, the highest dose
tested, adverse effects were not reported. In a dietary one-generation reproductive toxicity study with
pAOS in rats at up to 6,200 mg/kg body weight (bw) per day, the highest dose tested, no treatment-
related effects were observed.
The ANS Panel did not consider E 440i and E 440ii as having allergenic potential.
In humans (adults), a dose of 36 g/day (equivalent to 515 mg/kg bw per day) for 6 weeks was
without adverse effects.
The ANS Panel concluded that there is no safety concern for the use of pectin (E 440i) and
amidated pectin (E 440ii) as food additives for the general population and that there is no need for a
numerical ADI.
The ANS Panel, however, considered that the conclusions reached on the re-evaluation of the food
additive were not applicable to the use of pectin (E 440i) and amidated pectin (E 440ii) in food for
infants under the age of 12 weeks. They considered that these uses would require a specific risk
assessment.
Concerning the use of pectins (E 440) in ‘dietary foods for special medical purposes and special
formulae for infants’ (FC 13.1.5.1) and in ‘dietary foods for babies and young children for special
medical purposes as defined in Directive 1999/21/EC’ (FC 13.1.5.2), the ANS Panel concluded that the
available data do not allow for an adequate assessment of the safety of use of pectins (E 440) in
7 According to the EFSA Scientific Committee Guidance (EFSA Scientific Committee, 2017), this opinion will include infants up to
16 weeks of age.
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infants and young children consuming these foods for special medical purposes at the presently
permitted maximum use levels of 1%.
In addition, the following recommendations relevant for the current assessment were made:
• the European Commission considers lowering the maximum limits for the impurities of toxic
elements arsenic, lead, mercury and cadmium in the EU specifications for pectin (E 440i) and
amidated pectin (E 440ii) in order to ensure that pectin (E 440i) and amidated pectin (E 440ii)
as food additives will not be a significant source of exposure to those toxic elements in food;
special requirements might be defined in the specifications for pectin (E 440i) and amidated
pectin (E 440ii) to be used in formulae or food for infants, toddlers and other young children
• limits for aluminium should be considered for inclusion in the EU specifications, as aluminium
can be used in the manufacturing process
• the European Commission considers harmonising the microbiological specifications for
polysaccharidic thickening agents, such as pectins, and including criteria for the absence of
Salmonella spp. and Escherichia coli, for total aerobic microbial count (TAMC) and for total
combined yeasts and moulds count (TYMC) in the EU specifications for pectin (E 440i) and
amidated pectin (E 440ii)
• additional clinical data should be generated to assess the safety of pectins (E 440) when used
in ‘dietary foods for special medical purposes and special formulae for infants’ (FC 13.1.5.1)
and in ‘dietary foods for babies and young children for special medical purposes as defined in
Directive 1999/21/EC’ (FC 13.1.5.2)
2. Data and methodologies
2.1. Data
EFSA launched a public call for data8 to collect relevant information from interested business
operators.
The Panel based its assessment on information submitted to EFSA following the public call for data,
information from previous evaluations and additional available literature up to 1 December 2020.
To verify the use of the food additive pectin (E 440i) and amidated pectin (E 440ii) in food
products, the Mintel’s Global New Products Database (GNPD) was used. This database is an online
database which monitors new introductions of packaged goods in the market worldwide. It contains
information of over 3.4 million food and beverage products of which more than 1,300,000 are or have
been available on the European food market. Mintel started covering EU’s food markets in 1996,
currently having 24 out of its 27 member countries, and Norway and UK presented in the Mintel GNPD.
2.2. Methodologies
This opinion was formulated following the principles described in the EFSA Guidance on
transparency with regard to scientific aspects of risk assessment (EFSA Scientific Committee, 2009)
and following the relevant existing guidance documents from the EFSA Scientific Committee and in
particular the EFSA Guidance of the Scientific Committee on the risk assessment of substances present
in food intended for infants below 16 weeks of age (EFSA Scientific Committee, 2017).
In order to conclude on the safety of pectin (E 440i) and amidated pectin (E 440ii) for all
population groups and to address the data gaps identified during the re-evaluation, the FAF
Panel assessed the information provided:
• for the follow-up on issues that have been raised in the conclusions and recommendations of
the Scientific Opinion on the re-evaluation of pectin (E 440i) and amidated pectin (E 440ii) as a
food additive (EFSA ANS Panel, 2017) including the risk assessment of pectin (E 440i) and
amidated pectin (E 440ii) for the use as food additive in food according to food category (FC)
13.1.5.1 (dietary foods for infants for special medical purposes and special formulae for
infants) and FC 13.1.5.2 (dietary foods for babies and young children for special medical
purposes as defined in Directive 1999/21/EC) in infants above 16 weeks of age and young
children up to 3 years; and
8 Call for technical and toxicological data on pectin (E 440i) and amidated pectin (E 440ii) for uses as food additives in foods for
all population groups including infants below 16 weeks of age. Published: 18 July 2018. Available online: http://www.efsa.e
uropa.eu/en/consultations/call/call-technical-and-toxicological-data-pectin-e440i-and-amidated
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• for the risk assessment of pectin (E 440i) and amidated pectin (E 440ii) in food for infants
below 16 weeks of age in the FC 13.1.5.1 (Dietary foods for special medical purposes and
special formulae for infants).
When in animal studies, the test substance was administered in the feed or in drinking water, but
doses were not explicitly reported by the authors as mg/kg bw per day based on actual feed or water
consumption, the daily intake is calculated by the Panel using the relevant default values. In case of
rodents, the values as indicated in the EFSA Scientific Committee Guidance document (EFSA Scientific
Committee, 2012) are applied. In the case of other animal species, the default values by JECFA (2000)
are used. In these cases, the dose was expressed as ‘equivalent to mg/kg bw per day’. If a
concentration in feed or drinking water was reported and the dose in mg/kg bw per day was
calculated (by the authors of the study report or the Panel) based on these reported concentrations
and on reported consumption data for feed or drinking water, the dose was expressed as ‘equal to
mg/kg bw per day’. When in human studies in adults (aged above 18 years), the dose of the test
substance administered was reported in mg/person per day, the dose in mg/kg bw per day was
calculated by the Panel using a body weight of 70 kg as default for the adult population as described
in the EFSA Scientific Committee Guidance document (EFSA Scientific Committee, 2012).
The studies in neonatal piglets and the clinical trials were assessed for their risk of bias (RoB) by two
reviewers (members of the FAF Panel Working Group) applying an assessment tool modified from the
OHAT RoB tool (NTP-OHAT, 2015, 2019). The elements considered for the appraisal are described in the
Appendix B to this opinion, as well as the decision rule for assigning the studies to Tiers of reliability.
Dietary exposure to pectin (E 440i) and amidated pectin (E 440ii) from their use as a food additive
in foods for infants below 16 weeks of age was estimated combining the mean and high-level
consumption values reported for the period of 14–27 days of life which corresponds to 200 and 260
mL/kg bw per day (EFSA Scientific Committee, 2017), respectively, with the maximum levels according
to Annex II and Annex III, Part 5 Section B to Regulation (EC) No 1333/2008 and reported use levels
submitted to EFSA following a call for data. Different scenarios were used to calculate exposure (see
Section 3.4.1). Uncertainties on the exposure assessment were identified and discussed.
As pectin (E 440i) and amidated pectin (E 440ii) are also authorised in the food category 13.1.5.2,
an exposure assessment considering FC 13.1.5.1 and FC 13.1.5.2 was performed to estimate the
exposure of infants (above 16 weeks) and toddlers who may eat and drink these foods for special
medical purposes (FSMP). The consumption of these foods is not reported in the EFSA Comprehensive
database. To consider potential exposure to pectin (E 440i) and amidated pectin (E 440ii) via these
foods, the Panel assumes that the amount of FSMP consumed by infants and toddlers resembles that
of comparable foods in infants and toddlers from the general population. Thus, the consumption of
FSMP categorised as FC 13.1.5 was assumed equal to that of formulae and food products categorised
as FCs 13.1.1, 13.1.2, 13.1.3 and 13.1.4.
3. Assessment
3.1. Technical data
3.1.1. Identity of the substance
According to Commission Regulation (EU) No 231/20129, pectin (E 440i) consists mainly of the
partial methyl esters of polygalacturonic acid and their ammonium, sodium, potassium and calcium
salts. It is obtained by extraction in an aqueous medium of strains of appropriate edible plant material,
usually citrus fruits or apples.
Amidated pectin (E 440ii) consists mainly of the partial methyl esters and amides of
polygalacturonic acid and their ammonium, sodium, potassium and calcium salts. It is obtained by
extraction in an aqueous medium of appropriate strains of edible plant material, usually citrus fruits or
apples and treatment with ammonia under alkaline conditions.
Commission Regulation No 231/2012 differentiates between pectin (E 440i) and amidated pectin
(E 440ii) whilst JECFA (JECFA, 2016b) included both types of pectins (pectin and amidated pectin)
under the same food additive designation (INS 440).
9 Commission Regulation (EU) No 231/2012 of 9 March 2012 laying down specifications for food additives listed in Annexes II
and III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council Text with EEA relevance. OJ L 83,
22.3.2012, p. 1–295.
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Commercial pectins are divided into low-methoxy pectins (LM-pectins), where less than 50%
(typically 20–40%) of the carboxyl groups are methylated, whereas in high-methoxy pectins (HM-
pectins), more than 50% (typically 55–75%) are methylated (cite re-eval). In Lindinger et al. (1997), it
is stated that ‘natural pectin consists of joined galacturonic acid units, some of which are esterified
with methyl alcohol ranging from 30% in grapes typically to 75% in apples’.
The Panel noted that according to the interested business operators (documentation provided to
EFSA n. 5), the typical degree of methylation used in infant food is (50%–90%) for pectin (E
440i) and (20%–50%) for amidated pectin (E 440ii).
For more information on the physical properties and the chemical composition and structure of
pectin (E 440i) and amidated pectin (E 440ii) the reader is referred to the ANS Panel opinion (EFSA
ANS Panel, 2017).
3.1.2. Specifications
The specifications for pectin (E 440i) and amidated pectin (E 440ii) as defined in the Commission
Regulation (EU) No 231/2012 are listed in Table 1.
Table 1: Specifications for pectins (E 440i,ii) according to Commission Regulation (EU) No 231/2012
Commission Regulation (EU) No 231/2012 JECFA (2016b)
Pectin (E 440i) Amidated pectin (E 440ii) Pectins (INS 440)
Definition Pectin consists mainly of the
partial methyl esters of
polygalacturonic acid and
their ammonium, sodium,
potassium and calcium salts.
It is obtained by extraction
in an aqueous medium of
strains of appropriate edible
plant material, usually citrus
fruits or apples. No organic




mainly of the partial methyl
esters and amides of
polygalacturonic acid and
their ammonium, sodium,
potassium and calcium salts.
It is obtained by extraction
in an aqueous medium of
appropriate strains of edible
plant material, usually citrus
fruits or apples and
treatment with ammonia
under alkaline conditions. No
organic precipitant shall be
used other than methanol,
ethanol and propan-2-ol
Consists mainly of the partial
methyl esters of polygalacturonic
acid and their sodium, potassium,
calcium and ammonium salts;
obtained by extraction in an
aqueous medium of appropriate
edible plant material, usually citrus
fruits or apples; no organic
precipitants shall be used other
than methanol, ethanol and
isopropanol; in some types, a
portion of the methyl esters may
have been converted to primary
amides by treatment with
ammonia under alkaline conditions.
Sulfur dioxide may be added as a
preservative
Assay Content not less than 65%
of galacturonic acid on the
ash-free and anhydrous
basis after washing with acid
and alcohol
Content not less than 65%
of galacturonic acid on the
ash-free and anhydrous
basis after washing with acid
and alcohol
Not less than 65% of galacturonic
acid calculated on the ash-free and
dried basis
Description White, light yellow, light grey
or light brown powder
White, light yellow, light
greyish or light brownish
powder
White, yellowish, light greyish or
light brownish powder
Identification
Solubility Soluble in water forming a
colloidal, opalescent solution.
Insoluble in ethanol




Test for pectins – – Passes test(a)
Test for amide
group
– – Passes test (amidated pectins
only)(a)
Purity
Loss on drying Not more than 12%
(105°C, 2 h)
Not more than 12%
(105°C, 2 h)
Not more than 12% (105°C, 2 h)
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The Panel noted that no microbiological specifications are currently set for E440i and E440ii
according to Commission Regulation (EU) No 231/2012.
The revisions of the existing EU specifications proposed by the Panel are provided under
section 3.5.
3.1.2.1. Analytical data from commercial samples of the food additive
3.1.2.1.1. Toxic elements
The call for data, requested:
• analytical data on current levels of arsenic, lead, cadmium, mercury and aluminium in
commercial samples of the food additives;
• the lowest technologically achievable level for lead, mercury, cadmium, arsenic and aluminium
in order to adequately define their maximum limits in the specifications;
Analytical data were provided by one interested business operator for levels of arsenic (As), lead
(Pb), cadmium (Cd), mercury (Hg) and aluminium (Al) in commercial pectin (E 440i) and amidated
pectin (E 440ii) samples regarding the follow-up of the conclusions and the recommendations of the
EFSA ANS Panel opinion on the safety of pectin (E 440i) and amidated pectin (E 440ii) as food additives
of the EFSA call of data and this includes all age groups(documentation provided to EFSA n. 1).
Data on 15 independent batches were provided for toxic elements in pectin (E 440i). For arsenic,
one result was reported as 0.04 mg/kg and the remaining 14 batches were all reported as < 0.04 mg/kg.
For cadmium, one result was given as 0.01 mg/kg and 14 batches as < 0.01 mg/kg. All results for
mercury were reported as < 0.01 mg/kg. The lead levels ranged between < 0.015 and 0.431 mg/kg
(median: 0.036, mean: 0.097, P90: 0.26 mg/kg). All analyses were performed with inductively coupled
plasma-mass spectrometry (ICP-MS) with limits of quantification (LOQs) of 0.04 (As), 0.015 (Pb) and
0.01 (Cd, Hg) mg/kg, respectively. The determination of aluminium was performed with two methods,
ICP-MS (LOQ: 0.50 mg/kg) and ICP-Optical Emission Spectrometry (ICP-OES) (LOQ: 2.0 mg/kg). The
results maintained by ICP-MS and ICP-OES ranged from 0.81 to 99.0 (median: 26.7, mean: 40.0, P90:
87.2) mg/kg, and < 2.0–91.7 mg (median: 28.1, mean: 37.5, P90: 79.3) mg/kg, respectively.
Commission Regulation (EU) No 231/2012 JECFA (2016b)
Pectin (E 440i) Amidated pectin (E 440ii) Pectins (INS 440)
Acid insoluble
ash
Not more than 1% (insoluble
in approximately 3N
hydrochloric acid)
Not more than 1% (insoluble
in approximately 3N
hydrochloric acid)
Not more than 1%
Degree of
amidation
– Not more than 25% of total
carboxyl groups
Not more than 25% of total
carboxyl groups of pectin
Sulfur dioxide Not more than 50 mg/kg on
the anhydrous basis
Not more than 50 mg/kg on
the anhydrous basis
Not more than 50 mg/kg
Nitrogen
content
Not more than 1.0% after
washing with acid and
ethanol
Not more than 2.5% after
washing with acid and
ethanol
Not more than 2.5% after washing
with acid and ethanol
Total insoluble Not more than 3% Not more than 3% Not more than 3%
Solvent residues Not more than 1% of free
methanol, ethanol and
propan-2-ol, singly or in
combination, on the volatile
matter-free basis
Not more than 1% of free
methanol, ethanol and
propan-2-ol, singly or in
combination, on the volatile
matter-free basis
Not more than 1% methanol,
ethanol and isopropanol, singly or
in combination
Arsenic Not more than 3 mg/kg Not more than 3 mg/kg –
Lead Not more than 5 mg/kg Not more than 5 mg/kg Not more than 2 mg/kg for general
use and 0.5 mg/kg for use in
infant formula
Mercury Not more than 1 mg/kg Not more than 1 mg/kg –
Cadmium Not more than 1 mg/kg Not more than 1 mg/kg –
(a): For description, see JECFA (2016b).
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For amidated pectin (E 440ii), analytical data for toxic elements in 14 independent batches
were provided. All results for As and Hg were given as < 0.04 and < 0.01 mg/kg, respectively. For Cd,
one batch contained 0.01 mg/kg, all other batches were < 0.01 mg/kg. The lead levels ranged
between < 0.015 and 0.350 mg/kg (median: 0.042, mean: 0.095, P90: 0.26 mg/kg). All analyses were
performed by ICP-MS with LOQs of 0.04 (As), 0.015 (Pb) and 0.01 (Cd, Hg) mg/kg, respectively. The
determination of Al was performed with two methods, ICP-MS (LOQ: 0.50 mg/kg) and ICP-OES (LOQ:
2.0 mg/kg). The results maintained by ICP-MS and ICP-OES ranged from 0.59 to 201 (median: 16.9,
mean: 37.9, P90: 117.2) mg/kg, and < 2.0–178 mg (median: 16.8, mean: 35.2, P90: 107.5) mg/kg,
respectively.
On the question regarding the lowest technically achievable levels in pectin (E 440i) and amidated
pectin (E 440ii), the interested business operator stated: ‘Due to the ability of pectin molecules to bind
strongly with di-valent and tri-valent metal kations which may stem from raw materials or added as
processing aids (Calcium and Aluminium), IPPA considers the lowest technically achievable levels to be
as follows’, see Table 2.
The Panel noted that the analytical data on the toxic metals provided for the 29 independent
commercial E 440i and E 440ii samples are substantially lower than the lowest technically achievable
levels proposed by the business operator.
3.1.2.1.2. Microbiological criteria
The call for data, requested:
• Because of both the botanical origin and the polysaccharidic nature of pectin, they can be a
substrate of microbiological contamination. Data should be provided demonstrating the
absence of Salmonella spp. and Escherichia coli and on the lowest total aerobic microbial
count (TAMC) and total combined yeast and mould count (TYMC) that can be reached.
Microbiological data were provided for seven batches of pectin (E 440i) and six batches for
amidated pectin (E 440ii) (documentation provided to EFSA n. 1). In all samples, the total viable
count was < 10 CFU/g, the yeasts (incl. osmophilic yeasts) < 10 CFU/g, moulds (incl. xerophilic
moulds) < 10 CFU/g, E. coli negative in 10 g and Salmonella spp. negative in 25 g. The analyses were
performed with Deutsches Institut f€ur Normung (DIN) and/or ISO methods.
Due to the limited risk of contamination linked to the processing and packaging of commercial
pectin products, the business operator considers the lowest technically achievable microbial data to be
as follows:
• Salmonella spp.: negative by test in 25 g; E. coli: negative by test in 10 g; Total Aerobic plate
count (30°C): less than 500 CFU/g, and Total yeast and mould count (25°C): less than
100 CFU/g.
The business operator stated that the ‘Pectin production involves aqueous extraction of the raw
materials at elevated temperatures and acidic pH for a long time. Gram negative bacteria sensitive to
pasteurization – like E. coli and Salmonella spp – are thus eliminated at this stage. Further processing
involves precipitation and/or wash with alcohol followed by drying and milling in closed systems.
Accordingly microbial counts on pectin products are relatively low’. The same statement is given by the
business operator for the potential occurrence of Cronobacter sakazakii in E 440i and E 440ii.
The Panel noted that the analytical data submitted for the total aerobic plate count and the total
yeast and mould count are substantially lower than the respective proposed lowest technically
achievable values. Furthermore, the Panel noted that the statement on Cronobacter sakazakii
(documentation provided to EFSA n. 3,4) is not supported by analytical data, as no results nor lowest
technically achievable values were provided.
Table 2: Lowest technically achievable levels of the toxic elements As, Pb, Cd, Hg and Al in
commercial pectin products, as proposed by one interested business operator
(documentation provided to EFSA n.1)
Arsenic Lead Cadmium Mercury Aluminium
1 mg/kg 2 mg/kg 0.5 mg/kg 0.5 mg/kg 200 mg/kg
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3.1.3. Information on particular specifications in the additive for use in infant
formulae
The call for data, requested:
• Information on particular specification requirements for identity and purity of pectin (E 440i)
and amidated pectin (E 440ii) (e.g. content of toxic elements, methanol, ethanol, propan-2-ol,
sulfur oxide) in the special formulae for infants below 16 weeks of age under special medical
conditions (FC 13.1.5.1).
• Analytical data on impurities in the final special formulae for infants below 16 weeks of age
need to be provided when no legal limit has been established.
In addition, data were requested demonstrating the absence of Cronobacter (Enterobacter)
sakazakii.
One interested business operator provided information on residual alcohols and sulfur dioxide in
pectins (documentation provided to EFSA n. 3). According to their information, they currently only use
isopropanol as precipitation agent. The company claims that routine testing ensures that the content
of isopropanol never exceeds the legal limit, and the average content is reported as approximately
0.3%. Neither methanol nor ethanol is used in the production process of pectins. No information is
given on the frequency of the analyses nor on the total number of batches analysed. Following a
request for clarification, the interested business operator provided some information in relation to the
pectin material used in the study on neonatal piglets (Dilger, 2015; documentation provided to EFSA n.
3, 4). The Panel noted that the EU specification is met.
The same business operator informs that sulfur dioxide is not used in their manufacturing process
of pectins and that ‘past testing has indicated a level of SO2 at below 1 mg/kg (applied level of
detection)’. This demonstrates that pectins (E 440i,ii) can be produced without the use of sulfur
dioxide and, therefore, the limit value of 50 mg/kg in the EU specifications could be revised downward.
The Panel noted that the information provided by the business operators on the above impurities in
pectin (E 440i) and amidated pectin (E 440ii) in the final special formulae for infants below 16 weeks
of age is scarce.
Analytical data on arsenic and mercury in the final product for infants below 16 weeks of age were
provided for two companies by one interested business operator (documentation provided to EFSA n.
3,4). One company reported results in five batches of finished special medical purpose formula for
addition to human milk (utilising different/mixed vendor lots of pectins (E 440i)). In all five samples
analysed by ICP-MS, the results for arsenic and mercury were below the LOQ of 0.01 and 0.005 mg/kg,
respectively.
The second company submitted data on 66 batches of products in powder form containing pectins.
For mercury, all results were reported as ‘ND’ at an LOQ of 0.01 mg/kg. For arsenic, 16 samples had
concentrations between 0.02 and 0.05 mg/kg, the 50 remaining samples were below LOQ of 0.01 mg/kg.
Upon request the interested business operator submitted information on the method of analysis applied
in the analytical measurements of the second company and the procedure to establish the limit of
detection (LOD) and LOQ. The interested business operator informed that an in-house method based on
NF EN 15763 and NF EN 13805 was developed applying ICP-MS following digestion with HNO3/HCL/H2O2.
The Panel noted that analytical data on toxic elements in the finished products for infants below 16
weeks of age were submitted for arsenic and mercury for which legal maximum limits are not set in
Commission Regulation (EC) No 1881/200610. This interested business operator did not provide data
on toxic elements in pectin (E 440i) and amidated pectin (E 440ii) in the special formulae for infants
below 16 weeks of age under special medical conditions (FC 13.1.5.1). However, following a
clarification request they stated that ‘SNE, representing manufacturers of infant formula, does not
possess such information and we rely to the International Pectin Producers’ Association (IPPA) for this
request as they are in better position to provide those clarifications’. The Panel further noted that the
limit for lead in pectins in the specifications in the JECFA monograph (JECFA, 2016b) was reduced from
5 mg/kg to 2 mg/kg for general use, and a limit of 0.5 mg/kg was included for use in infant formula,
see Table 1 and Section 3.5.
Information on the typical degree of methylation for pectin (E 440i) and for amidated pectin
(E 440ii) when used in infant food was provided, see Section 3.1.1.
10 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in
foodstuffs (Text with EEA relevance). OJ L 364, 20.12.2006, p. 5–24.
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3.1.4. Stability of the substance, and reaction and fate in food
The call for data, requested:
• information on the fate and the reaction products of pectin (E 440i) and amidated pectin
(E 440ii) in the special formulae for infants below 16 weeks of age under special medical
conditions (FC 13.1.5.1).
Two companies provided information on fate and reaction products of pectins in the special
formulae for infants below 16 weeks of age under special medical conditions (documentation provided
to EFSA n. 3,4). One company determined the impact of processing conditions on pectin in
by analysing total uronic acid. Sample matrices analysed were two batches
of ‘pectin raw material’ from one vendor, before the sterilisation step (two batches, produced
using the pectin raw material), and after the final sterilisation step.
The company summarises the results of the analyses as follows:
‘The total uronic acid analysis showed the and pectin raw material contained analogous
amounts of total pectin, which demonstrates the total measured pectin amount in the HMF matches
the pectin amount added. The scope of this project was intended to include total uronic acid data in
both before and after the final manufacturing sterilization step (Steps 2 and 3 in Sample
Matrices section), however due to unforeseen circumstances (specifically, a fire at the [laboratory]11
site) the total uronic acid result in the after sterilization is not available. Nevertheless, in food
systems pectin depolymerization is a result of either acid hydrolysis or b-elimination. At low pH values
(pH < 3) acid hydrolysis is the predominant mechanism. At pH values (pH 5–7), b-elimination becomes
the predominant mechanism. The pH range for is pH 4.2–4.5 and was developed to avoid pectin
depolymerization during the UHT sterilization step and therefore is not expected to impact the total
uronic acid content of the finished product’. The Panel noted that no data are provided for after
sterilisation and therefore a conclusion on the impact of the sterilisation process on pectins cannot be
drawn. Furthermore, it concluded that the analysis of total uronic acid is not very specific as the
matrix contains additional UV active compounds which influence the analytical results of total uronic
acids.
The second company reports that they use pectin in powdered FSMP (containing less than 2%
humidity), packed under a protective atmosphere and claim that pectins are stable in the finished
product. During the process, pectins are solubilised in water before being blend with the other
ingredients of the infant formula.
In addition, the company reports on possible deesterification and depolymerisation of pectin based
on two publications (Sriamornsak, 2003 and Diaz et al., 2007):
‘Theorically, pectins, in solution, can go through 2 types of reactions, which compete with each
other:
• Deesterification, which occurs at low pH and low temperature
• Depolymerization, either by hydrolysis or by b-elimination. It occurs at a high temperature
(> 75°C) and at neutral or alkaline pH. It leads to an increase of both reducing sugars and
unsaturated uronides. However, the high level of carbohydrates in our products tend to limit
this reaction.
Once pectins are degradated, they lose their ability to form gel and to develop viscosity, so that it
will be visible in the finished product’.
Following a request for clarification, the interested business operators reported (documentation
provided to EFSA n. 5 that ‘during the production process of infant formulae, pectins are solubilized in
water before being blend with the other ingredients.
During the process, the pH is higher than the one tested by
Diaz et al. of pH 4.5 and it has been described that lower pH favors deesterification. Moreover, the
temperature used during the process are lower than the lowest one tested by Diaz of,12 at which the
11 Edited; the name of the laboratory site was removed.
12 The lowest temperature tested was 75°C.
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accumulation of methanol after 2 h (corresponding to the maximum process time) is very close to zero
(see Figure 1 in Diaz et al.)’.
Therefore, based on the above, the interested business operators consider that the deesterification
of pectins during the process is not relevant.
The Panel noted that the information on fate and reaction products of pectins in finished products
are very general and not supported by analytical data.
3.2. Authorised uses and use levels
Maximum levels of pectin (E 440i) and amidated pectin (E 440ii) in foods for infants below 16
weeks of age are defined in Regulation (EC) No 1333/2008 on food additives, as amended. In this
opinion, these levels are termed maximum permitted levels (MPLs).
According to Regulation (EC) No 1333/2008 pectin (E 440i) and amidated pectin (E 440ii) are
authorised in ‘dietary foods for infants for special medical purposes and special formulae for infants’
(FC 13.1.5.1) and in ‘dietary foods for babies and young children for special medical purposes’ as
defined in Directive 1999/21/EC’ (FC 13.1.5.2) at a maximum level of 10,000 mg/L, see Table 3.
Pectin (E 440i) and amidated pectin (E 440ii) are also authorised for uses in nutrient preparations
according to section B of Part 5 of Annex III to Regulation (EC) No 1333/2008, see Table 4.
3.3. Exposure data
Some food additives are authorised in the EU in infants’ formulae as defined by Commission
Directive 2006/141/EC (FC 13.1.1) and in dietary foods for infants for special medical purposes and
special formulae for infants (FC 13.1.5.1) at a specific MPL. However, a food additive may be used at a
lower level than the MPL. Therefore, actual use levels are required for performing a more realistic
exposure assessment.
Table 3: MPLs of pectin (E 440i) and amidated pectin (E 440ii) in foods according to the Annex II








13.1.5.1 Dietary foods for infants for
special medical purposes and
special formulae for infants
E 440 From birth onwards in products
used in case of gastro- intestinal
disorders
10,000
13.1.5.2 Dietary foods for babies and
young children for special
medical purposes’ as defined
in Directive 1999/21/EC
E 440 From birth onwards in products
used in case of gastro-intestinal
disorders
10,000
MPL: maximum permitted level.
Table 4: MPLs of pectin (E 440i) and amidated pectin (E 440ii) in foods for infants and young






Nutrient to which the
food additive may be
added
Food category
E 440 Pectins For uses in nutrient
preparations under the
condition that the maximum
level in foods mentioned in
point 13.1 of Part E of Annex
II is not exceeded
All nutrients Follow-on formulae and
processed cereal-based
foods and baby foods for
infants and young children
as defined by Directive
2006/125/EC
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In the framework of Regulation (EC) No 1333/2008 on food additives and of Commission
Regulation (EU) No 257/2010 regarding the re-evaluation of approved food additives, EFSA issued a
public call13 for technical and toxicological data on pectins (E 440) as a food additive for uses in foods
for all population groups including infants below 16 weeks of age. In response to this public call,
information on the actual use levels of pectins (E 440) in foods was made available to EFSA by
industry. No analytical data on the concentration of pectins (E 440) in foods were made available by
the Member States.
3.3.1. Reported use levels in food category 13.1.5.1
Industry provided EFSA with use levels (n = 10) of pectins (E 440) (documentation provided to
EFSA n. 3 and 4). The levels were provided by two companies. Levels of pectins were provided for
either for E 440i or E 440ii or also for both pectins. Industry indicated that these additives (E 440i and
E 440ii) are also used in combination with other thickening agents (xanthan gum (E 415) or locust
bean gum (E 410)) in the food category 13.1.5.1.
When levels were provided for both pectins, the two levels were added, and the sum was used as
occurrence level in the current exposure assessment (see Table 5).
3.3.2. Summarised data extracted from the Mintel’s Global New Products
Database
The Mintel’s GNPD is an online database which monitors new introductions of packaged goods in
the market worldwide. It contains information of over 3.4 million food and beverage products of which
more than 1,300,000 are or have been available on the European food market. Mintel started covering
EU’s food markets in 1996, currently having 24 out of its 27 member countries; Norway and UK
presented in the Mintel GNPD.14
For the purpose of this Scientific Opinion, Mintel’s GNPD15 was used for checking the labelling of
food and beverage products and food supplements for pectins (E 440) within the EU’s food market as
the database contains the compulsory ingredient information on the label.
No products intended for use in infants below 16 weeks were found in Mintel’s GNPD as labelled
with pectins (E 440). The additive is authorised for direct use according to Annex II to Regulation
N°1333/2008, in dietary foods for infants for special medical purposes and special formulae for infants,
therefore, for special formulae for infants described in Mintel as e.g. formulae for infants suffering from
allergies, regurgitation, . . . or for prematurely born infants. Both these types of formulae are not fully
covered in the Mintel GNPD.
3.4. Exposure estimates for infants and young children
Exposure to pectins (E 440) from their uses as food additives in formulae for infants below 16
weeks was estimated. This scenario is based on the recommended consumption levels from SC
Guidance (EFSA Scientific Committee, 2017). This guidance ‘recommends values of 200 and 260 mL
formula16/kg bw per day as conservative mean and high level consumption values to be used for
performing the risk assessments of substances which do not accumulate in the body present in food
intended for infants below 16 weeks of age’. These recommended consumption levels correspond to
14- to 27-day-old infants consumption. For the regulatory maximum level exposure assessment
scenario, MPL for special infant formulae (10,000 mg/kg for FC 13.1.5.1) was used. For the refined
scenario, reported use levels (maximum and mean) was considered.
3.4.1. Dietary exposure to pectins (E 440i, ii) from infant formulae
Table 5 summarises the estimated exposure to pectins (E 440i, ii) from their uses as food additives
in FC 13.1.5.1 for infants below 16 weeks of age.
13 Call for technical and toxicological data on pectins (E 440i,ii) for uses as a food additive in foods for all population groups
including infants below 16 weeks of age. Available online: http://www.efsa.europa.eu/en/consultations/call/call-technical-and-
toxicological-data-pectin-e440i-and-amidated
14 Missing Cyprus, Luxembourg and Malta.
15 http://www.gnpd.com/sinatra/home/ accessed on 15/9/2020.
16 The term ‘formula’ had been added.
Opinion on the re-evaluation of pectin (E 440i) and amidated pectin (E 440ii) as food additives
in foods for infants below 16 weeks of age and follow-up of their re-evaluation as food
additives for uses in foods for all population groups
www.efsa.europa.eu/efsajournal 18 EFSA Journal 2021;19(1):6387
The refined estimated exposure assessment scenario using the maximum use level reported by
industry was used in the assessment. The mean occurrence scenario is reported and indicates that
there are products on the market with giving lower exposure levels.
3.4.2. Exposure estimates for infants above 16 weeks of age and toddlers
consuming FSMP
As pectins (E 440i, ii) are authorised in the food categories 13.1.5.1 and 13.1.5.2, an additional
exposure assessment scenario considering these two food categories was performed to estimate the
exposure of infants (above 16 weeks) and toddlers (classified as young children in Commission
Delegated Regulation (EU) 2016/127, age of 1–3 years) who may eat and drink these FSMP. The
consumption of these foods is not reported in the EFSA Comprehensive database. To consider
potential exposure to pectins (E 440i, ii) via these foods, the Panel assumes that the amount of FSMP
consumed by infants and toddlers resembles that of comparable foods in infants and toddlers from the
general population. Thus, the consumption of FSMP categorised as FC 13.1.5 was assumed equal to
that of formulae and food products categorised as FCs 13.1.1, 13.1.2, 13.1.3 and 13.1.4. Levels for
only one sample of FC 13.1.5.2 was received for pectins (E 440i, ii); it was provided by pectins
producer which is then considered as recommended level and not as use level (see EFSA ANS Panel,
2017). The maximum level equals the MPL.
This scenario was estimated as follows:
– Consumers only of FSMP were assumed to be exposed to pectins (E 440i, ii) present at the
maximum reported use level on a daily basis via consumption of FC 13.1.5.1 and at the MPL
for FC 13.1.5.2. For the remaining food categories, the mean of the typical reported use levels
was used.
In the Food for Special Medical Purposes consumers only scenario, mean dietary exposure to
pectins (E 440) ranged from 9 mg/kg bw per day in toddlers to 434 mg/kg bw per day in infants
above 16 weeks of age. At the high level (95th percentile), dietary exposure to pectins (E 440) ranged
from 30 mg/kg bw per day up to 1,263 mg/kg bw per day in infants above 16 weeks of age.
For both infants and toddlers, the main contributing food category was Dietary foods for babies
and young children for special medical purposes as defined in directive 1999/21/EC (FC 13.1.5.2).
Table 5: Dietary exposure to pectins (E 440i, ii) in foods for infants below 16 weeks of age
according to Annex II to Regulation (EC) No 1333/2008 (in mg/kg bw per day)
Infants (< 16 weeks of age)
Regulatory maximum level exposure assessment scenario (10,000 mg/kg)
• Mean consumption (200 mL/kg bw per day)
• High-level consumption (95th percentile, 260 mL/kg bw per day)
2,000
2,600
Refined estimated exposure assessment scenario
Scenario using maximum use level reported by industry (4,170 mg/kg)
• Mean consumption (200 mL/kg bw per day)
• High-level consumption (95th percentile, 260 mL/kg bw per day)
834
1,084
Scenario using mean use level reported by industry (3,466 mg/kg)
• Mean consumption (200 mL/kg bw per day)
• High-level consumption (95th percentile, 260 mL/kg bw per day)
693
901
Table 6: Dietary exposure to pectins (E 440i, ii) in foods for infants above 16 weeks of age and
toddlers according to Annex II to Regulation (EC) No 1333/2008 (in mg/kg bw per day)
Infants (16 weeks–11 months) Toddlers (12–35 months)
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3.4.3. Uncertainty analysis
In accordance with the guidance provided in the EFSA opinion related to uncertainties in dietary
exposure assessment (EFSA, 2007), the following sources of uncertainty have been considered and
summarised in Table 7.
Pectins (E 440) is authorised in dietary foods for infants for special medical purposes and special
formulae for infants (FC 13.1.5.1) and in dietary foods for babies and young children for special
medical purposes as defined in Directive 1999/21/EC (FC 13.1.5.2) according to Annex II to Regulation
(EC) No 1333/2008 as well as in follow-on formulae and processed cereal based foods and baby foods
for infants and young children as defined by Directive 2006/125/EC according to Annex III to
Regulation (EC) No 1333/2008.
Based on the assumption that carers of children with allergy or any other medical disorders would
be brand-loyal to an infant formula for special medical purposes (FC 13.1.5.1) that suits his medical
disorder, the refined scenario using maximum use level reported by industry (Table 5) would in general
result in a reliable estimation of exposure for infants below 16 weeks of age with medical disorders.
The Panel noted that information from the Mintel GNPD indicated that no FSMP products for infant
and young children were labelled with pectins (E 440). These types of formulae are not fully covered
in the Mintel GNPD.
Considering that the maximum reported levels were used for foods under FC 13.1.5.1 and 13.1.5.2
while mean reported use levels were used for the rest of the diet, the Panel considered that the
dietary exposure to pectins (E 440) would result in a realistic estimation of the exposure to pectins
(E 440) from their uses as food additives according to Annex II for infants above 16 weeks of age and
toddlers.
It should be noted that the use according to Annex III to Regulation N°1333/2008 was taken into
account in the regulatory maximum level exposure assessment scenario. The maximum level
authorised according to the Annex III is ‘For uses in nutrient preparations under the condition that the
maximum level in foods mentioned in point 13.1 of Part E of Annex II is not exceeded’.
Table 7: Qualitative evaluation of influence of uncertainties on the dietary exposure estimate
Sources of uncertainties Direction(a)
Consumption data:
– one reference point only to estimate exposure during the period of up to 16 weeks of age
– consumption data: different methodologies/representativeness/underreporting/misreporting/
no portion size standard for subjects above 16 weeks of age
+/–
+/–
Methodology used to estimate high percentiles (95th) long-term (chronic) exposure based on
data from food consumption surveys covering only a few days for subjects above 16 weeks of
age
+
Correspondence of reported use levels to the food items in the EFSA Comprehensive Database:
uncertainties to which types of food the levels refer
+/–
Uncertainty in possible national differences in use levels of food categories +/–
Infants below 16 weeks of age:
Regulatory maximum level exposure assessment scenario:
– exposure calculations based on the MPL according to Annex II to Regulation (EC) No 1333/
2008
+
Infants below 16 weeks of age:
Refined exposure assessment scenarios:
– exposure calculations based on the maximum levels (reported use from industry)
– exposure calculations based on the mean levels (reported use from industry)
+/–
+/–
Infants above 16 weeks of age and toddlers:
– exposure calculations based on the maximum or mean levels (reported use from industry) +/–
(a): +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of
exposure.
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3.4.4. Exposure to methanol and formaldehyde
Please refer to Sections 3.6.2.5 and 3.6.2.6 for an assessment of the exposure to methanol and
formaldehyde following their release from pectins (E 440i,ii) in infants and young children.
3.5. Proposed revision to existing EU Specifications for pectin (E 440i)
and amidated pectin (E 440ii)
The Panel noted that the occurrence data on toxic elements submitted by the interested business
operators are substantially lower than the current limits in the EU specifications (documentation
provided to EFSA n. 1). The Panel emphasises that the maximum limits in the EU specifications for
toxic elements should be established based on actual levels in the commercial food additive. If the EC
decides to revise the current limits in the EU specifications, the estimates of toxic elements intake as
below could be considered.
All analytical results submitted by the interested business operators for As, Cd and Hg were either at
the LOQ or below the corresponding LOQ. The Panel considered that the LOQs can be taken as a
starting point to establish maximum limits for the specifications of these toxic elements in E 440i and
E 440ii. The LOQs of the methods of analysis (ICP-MS) used are the same for Cd and Hg, at 0.01 mg/kg
and at 0.04 mg/kg for As, respectively. Multiplying these values by a factor of 10 to account for
representativeness, homogeneity and analytical measurement uncertainty the maximum limit values for
the revision of the EU specifications could be derived as 0.1, 0.1, and 0.4 mg/kg, for Cd, Hg and As,
respectively.
The Pb concentrations reported by the interested business operator for commercial samples of
E440i and E440ii ranged between < 0.015 and 0.431 mg/kg (P90: 0.26 mg/kg). Based on IPC-MS
analysis, the Al levels in E440i and E440ii ranged from 0.81 to 99.0 (P90: 99.0) and 0.59 to 201 (P90:
117.2) mg/kg, respectively. The Panel considered the P90 value for Pb both in E440i and E440ii, and
the P90 for Al in E440ii rounded to 0.30 mg/kg and 120 mg/kg, respectively, as starting points to
establish maximum limits for these two elements.
The Panel emphasises that the choice of the factor and the percentiles, as well as other
considerations, such as on multiple sources of exposure to conclude on the maximum limits for toxic
elements in the specifications is in the remit of risk management. The numbers used here are merely
taken to support the risk assessment of these toxic elements as presented below.
The potential exposure to the toxic elements from the use of the food additives E 440i and E 440ii
can be calculated by assuming contamination of the additive may be up to the specifications limit
values and then by calculation pro-rata to the estimates of exposure to the food additive itself. With
regard to the dietary exposure to the food additive for infants below 16 weeks of age, the
Panel considered values of 200 and 260 mL formula/kg bw per day as conservative mean and high-
level consumption values, and the scenarios based on the regulatory maximum level exposure
assessment, and the reported use levels (refined scenario, Table 4). The group of infants above 16
weeks of age to 11 months of age has the highest exposure level among all population groups above
16 weeks.
The above-mentioned ‘modulated’ maximum limits combined with the estimated intakes of pectins
(E 440) could result in an exposure which can be compared with the following reference points or
health-based guidance values for the five elements; a BMDL01 of 0.3–8 lg/kg bw per day for arsenic
(EFSA CONTAM Panel, 2009a), a BMDL01 of 0.5 lg/kg bw per day for lead (EFSA CONTAM Panel,
2010), a TWI of 2.5 lg/kg bw per day for cadmium (EFSA CONTAM Panel, 2009b), a TWI of 4 lg/kg
bw for mercury (EFSA CONTAM Panel, 2012) and a TWI of 1 mg/kg bw for aluminium (EFSA, 2008).
The outcome of such an exercise (Table 8) illustrates the health impact that would result if the
calculated maximum limits for toxic elements were to be used.
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The same interested business operator provided lowest technically achievable levels for As (1.0 mg/kg),
Pb (2.0 mg/kg), Cd (0.5 mg/kg), Hg (0.5 mg/kg) and Al (200 mg/kg) in commercial pectins (E 440i and
E 440ii) (documentation provided to EFSA, for the purpose of defining appropriate specifications).
The health impact that would result if the maximum limits proposed by the interested business
operator are combined with the above-mentioned estimated intakes of pectins (E 440) is illustrated in
Table 9.
The resulting figures in both scenarios show that the exposure to toxic elements from the
consumption of E 440 is substantial. The Panel noted that the MOS/MOE for arsenic and lead are very
low. For arsenic the reference point is based on carcinogenicity for which the MOS/MOE should be at
least 10,000 (EFSA, 2005).
For lead, the reference point is based on a study demonstrating perturbation of intellectual
development in children with the critical response size of 1 point reduction in IQ. In the opinion on
lead (EFSA CONTAM Panel, 2010), it is mentioned that a 1 point reduction in IQ is related to a 4.5%
Table 8: Risk assessment for toxic elements based on the analytical data submitted by interested
business operator, and ‘modulated’ by the Panel, in pectins (E 440i and E 440ii) for use in
food for all age groups (Documentation provided to EFSA n. 1)




for As at 0.4
mg/kg
MOS/MOE
for Pb at 0.30
mg/kg
% of the TWI
for Cd at 0.1
mg/kg
% of the TWI
for Hg at 0.1
mg/kg
% of the TWI
for Al at 120
mg/kg
2,000(b) 0.38–10 0.83 56 35 168
2,600(b) 0.29–7.7 0.64 73 46 218
834(c) 0.90–24 2.0 23 15 70
1,084(c) 0.69–19 1.5 30 19 91
693(d) 1.1–29 2.4 19 12 58
901(d) 0.8–22 1.9 25 16 76
434(e) 1.7–46 3.8 12 7.6 36
1,263(e) 0.6–16 1.3 35 22 107
(a): Data from Table 5 (Section 3.4.1).
(b): Regulatory maximum level exposure assessment scenario.
(c): Refined estimated exposure assessment scenario – Scenario using maximum use level reported by industry (4,170 mg/kg).
(d): Refined estimated exposure assessment scenario – Scenario using mean use level reported by industry (3,466 mg/kg).
(e): Highest exposure level for the population above 16 weeks of age (FSMP consumers only scenario – 95th percentile; data
from Table 6 (Section 3.4.2).
Table 9: Risk assessment for toxic elements based on the lowest technically achievable limits in
pectins (E 440i and E 440ii) for use in food for all age groups as proposed by the
interested business operator (documentation provided to EFSA n. 1)









% of the TWI
for Cd at
0. 5 mg/kg
% of the TWI
for Hg at
0.5 mg/kg
% of the TWI
for Al at
200 mg/kg
2,000(b) 0.2–4 0.1 280 175 280
2,600(b) 0.1–3 0.1 364 228 364
834(c) 0.4–10 0.3 117 73 117
1,084(c) 0.3–7 0.2 152 95 152
693(d) 0.4–12 0.4 97 61 97
901(d) 0.3–9 0.3 126 79 126
434(e) 0.7–18 0.6 61 38 61
1,263(e) 0.2–6 0.2 177 110 177
(a): Data from Table 5 (Section 3.4.1).
(b): Regulatory maximum level exposure assessment scenario.
(c): Refined estimated exposure assessment scenario (Scenario using maximum use level reported by industry – 4,170 mg/kg).
(d): Refined estimated exposure assessment scenario (Scenario using mean use level reported by industry – 3,466 mg/kg).
(e): Highest exposure level for the population above 16 weeks of age (FSMP consumers only scenario – 95th percentile; data
from Table 6 (Section 3.4.2).
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increase in the risk of failure to graduate from high school and that a 1 point reduction in IQ in
children can be associated with a decrease of later productivity of about 2%. A risk cannot be
excluded if the exposure exceeds the BMDL01 (MOS/MOE lower than 1).
The MOS/MOE is calculated by dividing the reference point through the exposure estimate. The
assessment of the uncertainty in the exposure showed no potential to for overestimation of exposure
for the different scenarios with the exception of the regulatory maximum level exposure assessment
scenario (see Table 7). Hence, the MOS/MOE estimates are not underestimated with the exception of
that based on the MPLs. Even considering that the MOS/MOE might be underestimated using the
exposure estimates at the MPL, the order of magnitude between the MOS/MOE for arsenic and for
lead compared to the MOS/MOE requested (greater than 10,000 or greater than 1, respectively)
exceeds by far the possibility of being explained by an overestimation of the exposure.
Using the existing specifications for As (3 mg/kg), Pb (5 mg/kg), Cd (1 mg/kg) and Hg (1 mg/kg) in
E 440i and E 440ii, the exposure to toxic elements would be considerably higher and thus the resulting
MOS/MOE for As and Pb explicitly lower, and the exceedances of the TWIs for Cd and Hg distinctly
higher as illustrated in Table 10. Specifications for aluminium in pectins (E 440i and E 440ii) are
currently not set in Commission Regulation (EU) No 231/2012.
The Panel noted that the calculations clearly indicate the need to decrease the current maximum limits
for arsenic, lead, cadmium and mercury, and to set limit values for aluminium in pectins (E 440i and
E 440ii), considering also other sources of exposure to these toxic elements. Furthermore, the Panel noted
that maximum level for Pb and Cd in infant formula is set by Reg. 1881/2006; therefore, the
Panel calculated the impact of the concentration of the toxic elements Pb and Cd in the food additive on the
final product and compared that with the legal limits for elements in the final formula (see Appendix D).
Of note, at its 82nd meeting JECFA (2016b) reduced the limit for lead in pectins from 5 mg/kg to 2
mg/kg for general use, and a limit of 0.5 mg/kg was included for use in infant formula (JECFA, 2016a,b).
With regard to the maximum limit for sulfur dioxide (SO2), the business operator informed that this
compound is not used in the manufacturing process of pectin and that the past testing indicated a
level of SO2 at below the limit of detection of 1 mg/kg. This demonstrates that pectins (E 440i,ii) can
be produced without the use of sulfur dioxide and, therefore, the limit value of 50 mg/kg in the EU
specifications could be revised downwards.
With regard to maximum limits for solvent residuals, one interested business operator provided
information on residual alcohols in pectins (documentation provided to EFSA n. 3). According to their
information, they currently only use isopropanol as precipitation agent. The company claims that
routine testing ensures that the content of isopropanol never exceeds the legal limit, and the average
content is reported as approximately 0.3%. Neither methanol nor ethanol is used in the production
process of pectins. No information is given on the frequency of the analyses nor on the total number
of batches analysed. Following a request for clarification, the interested business operator provided
some information in relation to the pectin material used in the study on neonatal piglets (Dilger, 2015;
Table 10: Risk assessment for toxic elements based on the current limits for toxic elements in
pectins (E 440) for use in food for all age groups (Documentation provided to EFSA n. 1)
Exposure to E 440 (mg/





% of the TWI for
Cd at 1 mg/kg
% of the TWI for
Hg at 1 mg/kg
2,000(b) 0.05 – 1 0.05 560 350
2,600(b) 0.04 – 1 0.04 728 455
834(c) 0.1 – 3 0.12 234 146
1,084(c) 0.1 – 2 0.09 304 190
693(d) 0.1 – 4 0.14 194 121
901(d) 0.1 – 3 0.11 252 158
434(e) 0.23-6 0.23 122 76
1,263(e) 0.1-2 0.08 354 221
(a): Data from Table 5 (Section 3.4.2).
(b): Regulatory maximum level exposure assessment scenario.
(c): Refined estimated exposure assessment scenario (Scenario using maximum use level reported by industry (4,170 mg/kg)).
(d): Refined estimated exposure assessment scenario (Scenario using mean use level reported by industry (3,466 mg/kg)).
(e): Highest exposure level for the population above 16 weeks of age (FSMP consumers only scenario – 95th percentile; data
from Table 6 (Section 3.4.2).
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documentation provided to EFSA n. 3, 4). For the particular pectin used in this study, the Panel noted
that the EU specification is met.
According to the interested business operators (documentation provided to EFSA n. 5), the typical
degree of methylation used in infant food is (50–90%) for Pectin (E 440i) and (20–50%) for
amidated pectin (E 440ii).
Because of both the botanical origin and the polysaccharidic nature of pectins, they can be a
substrate prone to microbiological contamination. Therefore, the Panel noted that microbiological
specifications, including also Cronobacter (Enterobacter) sakazakii, should be set on the basis of the
information provided.
Overall, based on the analytical data provided by the interested business operators in response to
the EFSA call for data17 (documentation provided to EFSA n. 1, 3 and 4) and the above considerations,
the Panel recommends the following revisions of the existing EU specifications for pectins (E 440i and
E 440ii) as listed in Table 11.





Definition See Table 1 Unchanged
Assay See Table 1 Unchanged
Description See Table 1 Unchanged
Identification See Table 1 Unchanged
Solubility See Table 1 Unchanged
Purity See Table 1 Unchanged
Loss on drying See Table 1 Unchanged
Acid insoluble ash See Table 1 Unchanged
Degree of amidation See Table 1 Unchanged
Sulfur dioxide See Table 1 Lowered on the basis of the information provided
Nitrogen content See Table 1 Unchanged
Total insoluble See Table 1 Unchanged
Solvent residues See Table 1 Unchanged
Arsenic Not more than 3 mg/kg Lowered on the basis of the information provided and on
the considerations of the Panel
Lead Not more than 5 mg/kg Lowered on the basis of the information provided and on
the considerations of the Panel
Mercury Not more than 1 mg/kg Lowered on the basis of the information provided and on
the considerations of the Panel
Cadmium Not more than 1 mg/kg Lowered on the basis of the information provided and on
the considerations of the Panel
Aluminium Not presently specified To be included on the basis of the information provided
and the considerations of the Panel




Not presently specified Microbiological criteria should be included on the basis of
the information provided
E. coli Not presently specified Microbiological criteria should be included on the basis of
the information provided





Not presently specified Microbiological criteria should be included on the basis of
the information provided
17 Call for technical and toxicological data on pectin (E 440i) and amidated pectin (E 440ii) as a food additive for uses in foods
for all population groups including infants below 16 weeks of age. Published: 18 July 2018. Available from: https://www.efsa.
europa.eu/en/consultations/call/call-technical-and-toxicological-data-pectin-e440i-and-amidated.
Opinion on the re-evaluation of pectin (E 440i) and amidated pectin (E 440ii) as food additives
in foods for infants below 16 weeks of age and follow-up of their re-evaluation as food
additives for uses in foods for all population groups
www.efsa.europa.eu/efsajournal 24 EFSA Journal 2021;19(1):6387
3.6. Biological and toxicological data
3.6.1. Previous evaluation by ANS Panel (2017)
The following text (in italics) is from the opinion published in 2017 (EFSA ANS Panel, 2017). New
information and assessments related to the specific age group below 16 weeks of age are added in the
following paragraph.
Absorption, distribution, metabolism and excretion
Data on in vitro degradation of pectins and amidated pectins indicated that their digestibility was
low in the upper parts of the digestive tract, but they would be fermented during their passage
through the large intestine. These in vitro data are in agreement with in vivo studies demonstrating
the absence of degradation of pectins in germ-free rats by comparison to conventional animals. (. . .)
Knaup et al. (2008) investigated the human gastrointestinal metabolism of amidated pectin. (. . .)
Methanol liberation was observed (. . .). As demonstrated in ileostomy patients, the main end products
of this colonic anaerobic digestive process are SCFA, such as acetic, propionic and butyric acids, which
are absorbed from the colon and considered of no safety concern by the Panel. These data indicated
that pectins and amidated pectins would not be absorbed intact but extensively fermented by
intestinal microbiota in animals and humans.
Acute, subchronic, genotoxicity, chronic, developmental and reproductivity studies
The acute oral toxicity of pectin is low. Data on amidated pectin were not available, but a low acute
oral toxicity is expected based on the structural similarity to pectin.
In subchronic studies, after oral exposure (in the diet or drinking water) to non-amidated and/or
amidated pectins, the NOAEL ranged from 3,366 mg/kg bw per day (Takagi et al., 1997) to 13,500
mg/kg bw per day (Til et al., 1972). In subchronic studies with pAOS in the diet, the NOAEL ranged
from 1,700 to 3,400 mg/kg bw per day (Garthoff et al., 2010).
Although the available data were limited, there was no indication of genotoxicity for pectins. This
conclusion was also supported by the negative results obtained with manufactured pAOS (Garthoff
et al., 2010). Data on amidated pectin were not available, but considering its chemical structure and
its negligible absorption, the Panel considered that there is no concern with respect to genotoxicity for
amidated pectin.
A feeding study on chronic toxicity of pectin or amidated pectin in rats was available with sufficient
information for the evaluation of this endpoint, including data on a concurrent control (Palmer et al.,
1974; cited in Borzelleca et al., 1996). The NOAEL was 10% in the diet, equivalent to 5,000 mg/kg bw
per day.
Two reproductive toxicity studies and one developmental toxicity study with pectin, which were
considered inadequate for risk assessment, were available. In a dietary one-generation reproductive
toxicity study with pAOS in rats, a NOAEL of 6,200 mg/kg bw per day, the highest dose tested, was
identified.
Other studies
Five groups of pigs (n = 10, body weight 8.6  1.4 kg, 4 weeks of age) were fed a low-fibre (LF)
(raw wheat and barley flour), mid-fibre (MFH) and high-fibre (HFH) diets by adding barley hulls, or
mid- (MFP) and high- (HFP) fibre diets containing pectin (Genu pectin type B, 75% methylation) for
9 days (Hedemann et al., 2006). The pectin diets contained 71 g/kg pectin; the HFP diet contained, in
addition, 96 g/kg barley hulls. After 9 days, the animals were sacrificed and the entire gastrointestinal
tract was removed. The feed intake in the pectin-fed groups was decreased. The mucosal-enzyme
activity was affected by the fibre content of the diets in the MFH, MFP, HFH and HFP diet groups. The
villi and the crypts were shorter in the pectin groups, but the villous height/crypt ratio was unaltered.
The area of mucins in the crypts was decreased, suggesting that pigs fed pectin-containing diets are
more susceptible to pathogenic bacteria.
Hypersensitivity, allergenicity and food intolerance
Overall, in view of the available data, the Panel considered that there is no indication that the
reported immune-modulatory properties of pectin may lead to an adverse response, the data being
rather indicative of an effect which would limit the hypersensitivity response. Therefore, the Panel did
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not consider the food additives pectin (E 440i) and amidated pectin (E 440ii) as having an allergenic
potential.
3.6.2. Newly available data
3.6.2.1. Absorption, distribution, metabolism and excretion
No new data were submitted by the interested business operators or found in the provided
literature search (documentation provided to EFSA n. 1 - 4).
3.6.2.2. Toxicological data
Studies on neonatal piglets
In the former evaluation (EFSA ANS Panel, 2017), the summary of a 3-week dietary toxicity study
on pectins (E 440i and E 440ii) in farm piglets (MPI, 2013 as referred to in JECFA, 2015) was available.
This study and an additional study (Dilger, 2015) were briefly described. However, the study reports
were not available. The Panel received the full study reports (Documentation provided to EFSA n. 3,4).
The results of Dilger (2015) were also published by Fleming et al., 2020.
The two studies on neonatal piglets were assessed by means of a risk of bias (RoB) scoring scheme
(see Appendix B); both were allocated to tier 1 (low risk of bias).
The FAF Panel was provided with report and an amended version of the MPI study (MPI, 2013,
2014; documentation provided to EFSA n.3). This study followed the FDA (2006), EMA (2009) and ICH
(2010) guidelines. The study was performed according to Good Laboratory Practice (GLP). This 21-day
feeding study evaluated the impact of pectin in pre-weaning farm piglets (Yorkshire-bred, age 2 days)
on growth and development, including the gastrointestinal system (changes in gut microbiota, short
chain fatty acids and inflammatory findings). A milk replacer containing 0, 0.5, 3.0 or 10 g pectin/L
(GENU Pectin Type YM-100-L, 72% esterified) was given six times per day to groups of six males and
six female piglets, at a dose volume of 500 mL/kg bw per day (doses equal to 0, 130, 1,069 or 4,069
mg/kg bw per day). No treatment-related clinical signs were observed. Statistically significant
decreases were observed in male piglets of the high-dose group for the mean body weight at Day 21
(19.3%), mean food consumption at days 19–21 (up to 30%) and food efficiency during the entire
study period. In female piglets of the high-dose group a not statistically significant decrease (5%) in
mean body weight was observed starting on day 15. No changes in body weights were observed in
the mid- and low-dose groups (0.5 and 3.0 g/L) of females and males compared to controls. Re-
analysis of the data was performed using RMANOVA with sex included in the model. On days 17, 19
and 21, mean body weight of the high-dose group was found to be statistically decreased (12, 13 and
14% lower, respectively) as compared to controls based on the least square means. The decrease in
mean body weight in the high-dose group correlated with statistically significant decreases in food
efficiency. Statistically significant haematology findings were reported only in males, i.e. a reduction in
absolute reticulocytes at the high dose on day 14, which resolved by day 21, a reduction in platelets in
all treated males on day 21 and an increase in neutrophils on day 21 suggesting according to the
authors a slight elevation of an inflammatory response. Some statistically significant clinical chemistry
findings were also reported, i.e. a mild reduction in alkaline phosphatase (days 14 and 21) and
creatinine (day 14) in mid- and high-dose males, in aspartate aminotransferase (AST) and total
bilirubin on day 14 in high-dose males and in albumin (day 21) levels in the mid-dose males. The
authors concluded that the findings at a 10.0 g/L may be the result of the altered effects on growth at
this concentration. Some statistically significant effects were also observed in females, i.e. reductions
in total bilirubin (mid and high dose) and in Gamma-glutamyl transferase (GGT) (high dose) as well as
increases in globulin (high dose, on day 14) and total protein levels (mid dose). The Panel noted that
the findings in haematology and clinical chemistry were not consistent between sexes, not clearly
dose-related or resolved at day 21 and therefore considered that they may not be toxicologically
relevant. Also, none of the fluctuations in urinalysis were considered toxicologically meaningful.
Analysis of short-chain fatty acid (e.g. acetic, propionic and butyric acids) in the caecum and colon
showed an increase in the short-chain fatty acids (SCFA) in large bowel contents with increasing pectin
concentrations in the diet. There was a decrease (trend) in pH level of the caecum and colon contents,
which may be related according to the authors to the production of SCFA by endogenous microbiota.
The authors considered that the evaluation of the intestinal microbiota in piglets indicate that based on
the large inhomogeneities between individuals, there may be a strong host-dependent composition of
the bacterial microbiota regardless of dietary treatments. There were no statistically significant
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changes in absolute and relative organ weights – except for increases in caecum and colon weights in
the mid- and high-dose groups of females and males. No relevant macroscopic findings were reported.
The microscopic evaluation indicated a slight increase of subacute inflammation (minimal to mild) in
the caecum and colon of females and males of the high-dose group compared to controls. However,
no systemic inflammation was assumed by the authors due to the absence of changes in blood
cytokines (IL-1 beta, IL-6, IL-8 and TNF-alpha). According to the authors, the NOAEL for this study
was the mid-dose, 1,069 mg/kg bw per day, based on decreased body weight in piglets irrespective of
sex at the highest dose (4,069 mg/kg bw per day, males). The Panel agreed with this conclusion.
The FAF Panel was provided with the original report of a non-GLP study described in the EFSA
Panel opinion (EFSA ANS Panel et al., 2017) as (Dilger, 2015; documentation provided to EFSA n. 3,4)
and the publication of this study (Fleming et al., 2020). The study was conducted to evaluate the
impact of pectin in pre-weaning farm piglets (Domestic Yorkshire Crossbred Swine Yorkshire-bred, age
2 days) on growth and digestibility. Pectin was derived from citrus peel (GENU® pectin type YM-100-L,
72% esterified). The pectin-containing ingredient was analysed to contain 45.1% pectin, with sucrose
as the majority of the remaining product. Six piglets/sex per treatment group (controls: 5 males18 and
7 females) were administered pectin in milk replacer as their sole source of nutrition for 3 weeks from
postnatal day 2 at a target concentration of 2 or 10 g/L (equal to 704 and 4,461 mg/kg bw per day,
respectively, for males and females combined). Faeces were collected and weighed on study days
12–14 (phase 1) and 19–21 (phase 2). On day 21, pigs were euthanised and digesta from the middle
of the ileum (defined as the distal 20% of the small intestine proximal to the ileocecal junction) were
collected. Quantification of the digestibility was measured by incorporation of ytterbium chloride as an
indigestible liquid marker from day 10–21. Apparent ileal digestibility (AID) and apparent tract total
digestibility (ATTD)19 of nutrients for dry matter and crude protein and energy were measured. The
differences in the analyses of the diets of the organic matter, crude protein and gross energy were
minimal. Diets of the control and the 2 g/L group exhibited similar viscosity. The 10 g/L group showed
a higher viscosity and was ‘thick’ and slow flowing compared to the control and the 2 g/L group. All
pigs exhibited loose stool from days 2–4; this is considered as a common effect for artificial reared
pigs. No treatment-related clinical signs were noted. Consumption of milk replacer and growth (from
day 11) and feed efficiency were significantly reduced in the 10 g/L group. In the high-dose group
final body weight, body weight gain, feed intake and feed efficiency were lower than in the control
group (27%, 38%, 19% and 23%, respectively); no such differences from controls were observed in
the lower dose group. In addition, a significantly reduced digestibility (AID and ATTD) in the 10 g
pectin/L group was reported. According to the authors, the NOAEL for this study was 2 g pectin/L
(704 mg pectin/kg bw per day) based on these findings. The Panel agreed with this conclusion.
Other studies from the literature
A study investigating protective effect of Banana Pectin Extract on aluminium absorption and its
impairment of cognitive function was conducted in mice (Zeng et al., 2018; documentation provided
to EFSA n. 2). IRC male mice (7 weeks old at the start of the treatment, n = 12/group) received intra-
gastrically (by gavage) 0.9% NaCl (vehicle control), 35 mg aluminium/kg bw per day, or 100 mg
banana pectin and 35 mg aluminium/kg bw per day for 42 days. The banana pectin contained 79.56 
1.81% of galacturonic acid and 2.38  0.10% of protein and the degree of esterification was 64.73 
1.37%. The percentage of galacturonic acid complies with the specifications of pectin (E 440i). At the
end of the treatment, body weight gain was similar in the control group and the banana pectin group
(97% of the control). The Panel noted that daily administration by gavage of 100 mg banana pectin/kg
bw for 42 days had no adverse effect on body weight gain of mice as compared to the controls.
A literature study investigating effects of animal or plant origin protein and indigestible
carbohydrates on concentration of short-chain fatty acids in the large intestine in growing pigs was
provided (Taciak et al., 2017; documentation provided to EFSA n. 2). Due to the poor reporting of
toxicological relevant endpoints including body weight results, this study does not provide information
relevant for the risk assessment of pectins (E 440i, ii) as food additive.
18 A total of 17 intact males and 19 females were delivered to the laboratory).
19 AID is a measure of the energy and nutrients absorbed by the host within the gastrointestinal tract prior to the distal end of
the ileum, and ATTD is a measure of the nutrients and the energy that are both absorbed by the host and fermented/
metabolised by the colonic microbiota. While both AID and ATTD are well-accepted and standard methods to measure
nutrient and energy digestibility, AID can be considered to better represent nutrient and energy available to the pig, as energy
and other nutrients have not been affected by bacterial fermentation to an appreciable extent prior to the caecum.
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3.6.2.3. Clinical data
Studies with pectins
The following seven references of clinical studies were submitted by the interested business
operators in response to the call for data launched by EFSA: Dupont et al., 2015; Vandenplas et al.,
2016; Dupont et al., 2016a; Vandenplas et al., 2014; Rossetti et al., 2019; Dupont and Vandenplas,
2016b, 2019 (Documentation provided to EFSA n.3).
The Panel noted that according to the publications, it was not the primary aim of the studies to
investigate the influence of pectins and amidated pectins (E 440i; E 440 ii) on the development of
weight or on the tolerability in infants with the exception of the study of Vandenplas et al., 2016. The
publications do not contain information on the composition of the formulas tested. However, the
interested business operator provided information on the content of pectins (E 440i) and amidated
pectins (E 440ii) (Documentation provided to EFSA n.3). The Panel noted that the formulae used in
the clinical studies contained a combination of pectin (E 440i) and amidated pectin (E 440ii) with
locust bean gum or xanthan gum. The Panel noted that thickening agents have similar properties.
The studies were assessed by means of a risk of bias (RoB) scoring scheme. The reviewers gave
identical RoB scores for all studies (see Appendix C for further details). Only minor inconsistencies on
the scoring for some of the questions/elements were noted and clarified. All studies were allocated to
tier 3 (high risk of bias).
In the study of Dupont et al., 2015, infants suffering from cow’s milk protein allergy were
allocated to two formulas. The composition of the formulas is not given, but just mentioned that the
test formula ‘had a similar nitrogen content (1.9 g/100 mL20) and differed mostly by the presence of a
patented thickening mixture including fibres (0.5 g/100 mL), mainly composed of pectin, which
thickens at gastric pH compared to the control formula’. No anthropometric data are given. The age is
given as < 18 months. No data on growth development are given. Concerning the safety, the authors
state ‘the most common adverse events were gastrointestinal tract affections and infections and were
not related to the study product and that the incidence of adverse events was not different between
groups’. Because of lacking information, this study does not contribute to the assessment of the safety
of pectins (E 440i) and amidated pectins (E 440ii). The study was allocated to tier 3 in the RoB
assessment.
The study of Vandenplas et al. (2016) is an extension of a study with a duration of 1 month
(Vandenplas et al., 2014) and reports on the outcome after 3 months and 6 months. Infants with cow
milk allergy and regurgitations or frequent vomiting below 6 months were recruited for this study. The
primary aim was to report on anthropometric data after 6 months. The study has several major flaws.
The number of participants was in the beginning 36 infants in the group allocated to the formula with
thickener and 41 infants in the group allocated to the formula not containing the thickener. At
6 months, the number of participants was 20 in the group treated with thickener containing formula
and 20 in the group treated with formula containing no thickener. This corresponds to more than 20%
of drop out and by this invalidates the results of the study (Genaidy et al., 2007). The detailed
composition of the formulae is not reported. For the thickener containing formula the publication
reports that the formula contains 3.6 g fibres/100 g of powder and 1.0 g starch/100 g of powder
which is different from the composition the interested business operator has reported for this study
after which the formula does not contain starch but xanthan gum (E 415) in addition to pectins and
amidated pectins (E 440i and E 440ii). No information is given as to whether infants in both groups
received complementary feeding. The anthropometric data were compared with non-randomised
comparisons (i.e. comparisons to historical controls, such as comparisons to growth reference charts
the data of which are of observational nature. Because of lacking information, this study does not
contribute to the assessment of the safety of pectins (E 440i) and amidated pectins (E 440ii). The
study was allocated to tier 3 in the RoB assessment.
The study of Dupont et al. (2016a) was a non-randomised, non-controlled prospective and
multicenter study in 30 infants with a mean age of 4.8  3 months diagnosed with cow milk allergy.
The authors describe the tested formula given for 4 months as ‘Allernova AR®, Novalac, United
Pharmaceuticals, France contains an extensively casein-based hydrolysate as protein source and is
thickened with a patented complex containing fibres (0.5 g/100 mL), mainly composed of pectin, to
reduce regurgitation but also to help intestinal transit regulation.’ According to the information of the
interested business operator the formula contains xanthan gum (E 415) in addition to pectins and
20 Assumed by the Panel as 1.9 g protein/100 mL.
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amidated pectins (E 440i and E 440ii). The study was aimed at demonstrating beneficial effects of the
formula and no specific section addresses the safety. The outcomes in terms of weight gain or height
development cannot be interpreted with respect to the effect of pectin (E 440i) and amidated pectin
(440ii) as the study had no control group. Because of lacking information and methodological
limitations (absence of randomisation), this study does not contribute to the assessment of the safety
of pectins (E 440i) and amidated pectins (E 440ii). The study was allocated to tier 3 in the RoB
assessment.
The study of Vandenplas et al. (2014) was a non-randomised, non-controlled study in 40 infants
with a mean age of 3.4  1.5 months diagnosed with cow milk allergy. The authors describe the
tested formulae given for 6 months as containing 0.5 g fibre/100 mL or 0.5 g fibre/100 mL and 0.1 g
starch/100 mL which is different from the composition the interested business operator has reported
for this study after which the formula does not contain starch but xanthan gum (E 415) in addition to
pectins and amidated pectins (E 440i and 440ii).The study was aimed at demonstrating beneficial
effects of the formula and no specific section addresses the safety. The authors described 79 adverse
events and 5 severe adverse events (infections) and state that they were not related to the study
formula with no further comments. The absence of a control group does not allow to draw any
conclusions. The outcomes in terms of weight gain or height development cannot be interpreted with
respect to the effect of pectin (E 440i) and amidated pectin (440ii) as the study had no control group.
Because of lacking information and methodological limitations (absence of randomisation), this study
does not contribute to the assessment of the safety of pectins (E 440i) and amidated pectins (E 440ii).
The study was allocated to tier 3 in the RoB assessment.
The aim of the study of Rossetti et al. (2019) is described as ‘the primary objective of this study
was therefore to evaluate the hypoallergenicity of a new thickened extensively hydrolyzed casein-
based formula (TeHCF) in children with CMA [cow milk allergy]’. The authors describe the tested
formula as ‘Allernova, new thickener (Novalac, United Pharmaceuticals, Paris, France)] had an energy
density of 67 kcal/100 mL and contained 1.6, 3.5, 6.9 and 0.5 g of proteins, lipids (including
arachidonic acid and docosahexaenoic acid), carbohydrates and fibre per 100 mL, respectively. The
new thickener was a patented mix of fibres, including pectin and locust bean gum’ which is close to
the composition the interested business operator has reported for this study. The study was a non-
randomised, non-controlled study in 29 infants with a mean age of 8.03  7.43 months treated over
90 days. The outcomes in terms of weight gain or height development cannot be interpreted with
respect to the effect of pectin (E 440i) and amidated pectin (E 440ii) as the study had no control
group. Because of lacking information and methodological limitations (absence of randomisation), this
study does not contribute to the assessment of the safety of pectins (E 440i) and amidated pectins
(E 440ii). The study was allocated to tier 3 in the RoB assessment.
The aim of the study of Dupont and Vandenplas (2016b) is described as: ‘This prospective
international open pilot multicentre clinical trial was conducted to evaluate the efficacy of a new
formula (Novalac, Paris, France) on regurgitation and defecation.’ One hundred patients less than
5 months old with regurgitations entered the study, after 14 days 90 patients remained in the study
and were treated for 90 days. During that period 11 patients dropped out and were lost to follow up.
Weight was followed up but no specific information was reported in the publication concerning safety.
The outcomes in terms of weight gain or height development cannot be interpreted with respect to
the effect of pectin (E 440i) and amidated pectin (440ii) as the study had no control group. Because of
lacking information and methodological limitations (absence of randomisation), this study does not
contribute to the assessment of the safety of pectins (E 440i) and amidated pectins (E 440ii). The
study was allocated to tier 3 in the RoB assessment.
The publication of Dupont and Vandenplas (2019) is a review reporting retrospectively on four
open label, interventional, single-group, multi-centric clinical trials (including Dupont and Vandenplas,
2016b). The test formulae (United Pharmaceuticals SAS/Novalac, Paris, France) were cows’ milk based
and contained a thickening complex composed of pectin, locust bean gum and either tapioca or corn
starch. The exact composition of the thickening complex varied between the test formulae. Weight
was followed up but no specific information was reported in the publication concerning safety.
The outcomes in terms of weight gain or height development cannot be interpreted with respect to
the effect of pectin (E 440i) and amidated pectin (E 440ii) as the studies had no control group. The
adverse events are described in the safety population. The authors stated that 141 adverse events
have been reported in the four studies without mentioning the measures taken to collect adverse
events. They further report that ‘Seven of them were serious adverse events, of which none were
considered related to the study formula’ without giving details on the method to judge on the
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relationship between event and study formula. The events concerned respiratory and ear, nose and
throat infections, gastrointestinal symptoms including gastroenteritis, distress and crying, allergic
reactions and other troubles including pyrexia, roseola and fungal infection. Twenty-nine non-serious
adverse events were considered to be related to the study formula by the investigators, as reported by
the authors. Most of these events were mild to moderate in terms of severity and related to the
gastrointestinal tract: eight had constipation, five diarrhoea, seven colic/abdominal pain and five
worsening of regurgitations. The review cannot be assessed with the RoB tool as relevant details are
lacking. Because of the lack of a control group, the single studies would have to be allocated to tier 3
in the RoB assessment.
In the former EFSA opinion a multicenter, third-party-blinded, randomised-controlled, prospective
study, in preterm infants is described (Moya et al., 2012). In this study, the infants were fed with
human milk to which either a pectin-containing (0.085% pectin21) so-called fortifier or another fortifier
(control) was added. The publication does not contain information on the content of pectin in the
tested so-called fortifiers. From 75 infants recruited for the study, 74 consumed the tested fortifier and
51 completed the study whereas in the control group 72 consumed the fortifier and 55 completed the
study. Hence, in both arms, the attrition rate is greater than 20% and by this the results of the study
are invalidated (Genaidy et al., 2007). At 14 days with 66 infants in the control group and 65 infants in
the tested group not differences were seen between the two groups, whereas at 28 days, the infants
fed the tested so-called fortifier milk achieved a higher linear growth rate and greater increase in
weight and length but no difference in head circumference compared with the control formula. In the
study only specific life threatening side effects were explicitly collected but no other side effects.
Because of the many limitations, the study was allocated to Tier 3.
The Panel notes the methodological limitations of several clinical studies (absence of randomisation;
no control group). The Panel also notes that all studies had a high risk of bias. The Panel considers
that no conclusions can be drawn from the clinical studies with respect to the assessment of the safety
of pectins and amidated pectins.
Studies with pectin-derived acidic oligosaccharides
The following references of clinical studies performed with pectin-derived acidic oligosaccharides
were submitted by the interested business operators in response to the call for data launched by
EFSA: Fanaro et al., 2005; Harvey et al., 2014; Burks et al., 2015; Harvey et al., 2017; Magne et al.,
2008; Piemontese et al., 2011; Westerbeek et al., 2008, 2010 (Documentation provided to EFSA n.3).
JECFA (2015) concluded that studies using pAOS were relevant for the evaluation of pectins in infant
formulae. The ANS Panel agreed with this conclusion (EFSA ANS Panel, 2017).
The studies were assessed by means of a risk of bias (RoB) scoring scheme. The reviewers gave
identical RoB scores for all studies (see Appendix C for further details). Only minor inconsistencies on
the scoring for some of the questions/elements were noted and clarified. All studies were allocated to
tier 3 (high risk of bias).
In the study of Fanaro et al. (2005), a mixture of 80% neutral oligosaccharides form long-chain
galacto (GOS)- and long-chain fructooligosaccharides (FOS) with 20% acidic oligosaccharides (AOS)
was investigated in a three armed prospective, randomised (method not mentioned) study in healthy
children (age not given, most probably newborn). A standard formula was fed to which (1) maltose
(0.8 g/100 mL) (control group), or (2) 0.2 g/100 mL acidic oligosaccharides (+ acidic OS) plus 0.6 g
maltose/100 mL or (3) 0.2 g/100 mL acidic oligosaccharides plus 0.6 g/100 mL neutral
oligosaccharides (+ acidic+ neutral OS) was added. The composition of the formulas was not disclosed.
The study lasted for 6 weeks and measurements were performed at day 1 and at the end of the study.
The primary endpoint was the intestinal flora; further endpoints were stool characteristics, pH of stool
and tolerance. Incidence of crying, regurgitation and vomiting was to be recorded by the mothers.
Five of the infants enrolled did not complete the study; however, it is not indicated from which study
arm the infants dropped out. No information is given on the amount per day consumed. Weight gain
and length gain did not differ between the groups and the stool became softer in the study groups
(n = 16 + acidic OS and n = 15 + acidic + neutral OS) compared to the control group (n = 15). No
information was given on the tolerability but at the end of the discussion the authors claim that ‘pectin
hydrolysates . . . were well tolerated as a supplement to an infant formula’. In the abstract, the authors
claimed that the study was double blind but, in the methods section, there is no indication that the
21 The content of pectin was reported in JECFA. . ..
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study was blinded. Because of methodological flaws, the study was allocated to tier 3 and does not
provide relevant information on the safety of pectins in infants.
The publication of Harvey et al. (2014) reports on two clinical studies, the first in 115 healthy
infants with a duration of 16 weeks, the second in 30 infants and children with cow milk allergy with a
duration of 7 days. Because of the short duration the latter study is not included into this assessment.
The first study was a randomised (method not mentioned), blinded (method not mentioned) study
with a control group (n = 56) receiving a commercially available Neocate Infant DHA and ARA whereas
the test group (n = 59) received Neocate Infant DHA and ARA with synbiotics (combination of
Bifidobacterium breve M-16V as probiotic and a combination of neutral fructooligosaccharides and
pectin-derived acidic oligosaccharides as the prebiotic). The composition of the two preparations is not
given in detail. According to the abstract, the primary outcome measures were weight, height and
head circumference. Secondary endpoints were stool characteristics and gastrointestinal symptoms. In
the abstract, the authors also state that clinical examinations, dietary intake, clinical laboratory results
and adverse events were recorded. Investigations were made in week 2, 4, 12 and 16. The drop out
from the study was high with 115 infants entering the study; 54.2% of the infants completed the
study in the test group, which had started with 59 infants and 67.9% in the control group which had
started with 56 infants. Statistical procedures are not fully described (intent to treat without describing
the method how the values of the drop outs were handled) and the numbers of infants in the study by
week 16 given for gastrointestinal side effects differ from the number of in infants which completed
the study (gastrointestinal side effects n = 29 for the control and reported as completed 38; n = 27 for
the test and reported as competed n = 32). Therefore, all the reported results may have been heavily
biased and can only be assessed with low confidence. According to the authors, there is no difference
between the two groups in the course of the study. Because of the methodological flaws, the study
was allocated to tier 3 and does provide no relevant information on the safety of pectins in infants.
The study of Burks et al. (2015) was a randomised (method not mentioned), blinded (method not
mentioned) study with a control group (n = 56) receiving a commercially available Neocate Infant DHA
and ARA) whereas the test group (n = 54) received Neocate Infant DHA and ARA with synbiotics
(combination of Bifidumbacterium breve M-16V as probiotic and a combination of chicory-derived
neutral oligofructoses, long-chain inulin and pectin-derived acidic oligosaccharides as the prebiotic).
The composition of the two preparations is not given in detail, but reference is made to the publication
of Harvey et al. (2014) (see above). The infants, aged 0.6–8.9 months, had to have a confirmed cow
milk allergy. The primary outcome parameter was weight, length and head circumference. Secondary
outcome parameters were a scale for allergic skin lesions, allergic symptoms, stool parameters,
formula intake faecal microbiota, faecal pH and short- chain fatty acids. Furthermore, safety
parameters were recorded (adverse events, medication use, blood parameters and clinical chemistry).
From the 110 infants in the study 90 completed the study. Weight, length and head circumference
were not statistically different. Formula intake was not reported and difference between groups could
not been ruled out. As more than 50% participants had an age above 4 months complimentary
feeding is to be expected which had not recorded. Therefore, these findings are hard to interpret with
respect to the influence of the tested formula. A statistically significant difference was noted for the
number of adverse event with the symptom diarrhoea (more frequent in the test group compared to
control group) and the symptom infection (more frequent in the control group compared to the test
group). Drugs for functional gastrointestinal disorders and antibacterial drugs for systemic use were
more often needed in the test group compared to the control group. These differences cannot be
attributed to the composition of the formulas with the reasons given above. Because of many
methodological flaws, the study was allocated to tier 3 and does not provide relevant information on
the safety of pectins in infants.
The study of Harvey et al. (2017) aimed at assessing the mineral status (calcium, phosphorus,
chloride, sodium, potassium, magnesium and iron) of infants receiving an amino-acid-based formula.
The participants of this evaluation were the identical with the infants in the Burks et al. (2015) study,
described above. The results are not split up into control and test group but are given for all
participants in the Burks et al. (2015) study. Hence, the study results cannot be attributed to the
group having been fed with pectin-derived acidic oligosaccharides. Therefore, the study does not
provide relevant information on the safety of pectins in infants.
The aim of the study of Piemontese et al. (2011) was ‘to assess the tolerance and safety of a
formula containing an innovative mixture of oligosaccharides in early infancy’. The study was a multi-
centre, randomised, double-blind, placebo-controlled trial performed in healthy, term infants, with a
normal birth weight. A total of 830 infants were randomised before the age of 8 weeks to feeding with
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a formula containing 6,800 mg/L of neutral short-chain galacto-oligosaccharides (scGOS) and long-
chain fructo-oligosaccharides (lcFOS), ratio 9:1 and 1,200 mg/L pectin derived acidic-oligosaccharides
(study group, n = 414), or with a formula without oligosaccharides (control group, n = 416). A total of
300 non-randomised breast-fed infants was used as a reference group. Anthropometric parameters
(weight, length, head circumference, mid-upper arm circumference, triceps and subscapular skinfolds),
gastrointestinal tolerance (regurgitations, vomiting, stool frequency and consistency) and adverse
events were assessed at 8, 16, 24 and 52 weeks of age. There was no difference in the dropouts
between both groups. No differences were reported in anthropometric parameters, gastrointestinal
tolerance and adverse events between infants fed the formula containing oligosaccharides and infants
fed the control formula. Stool consistency was significantly lower in the study group at 8, 16 and 24
weeks compared to the control group and closer to that of the breastfeeding group. Because of the
presence in the study formula of not only pectin-derived acidic oligosaccharides but also scGOS and
lcFOS, this study does not contribute to the assessment of the safety of pectins. The study was
allocated to tier 3 in the RoB assessment.
The aim of the study of Magne et al. (2008) was ‘to test the safety and effect on faecal
microbiota of a formula with prebiotic oligosaccharides alone or in combination with acidic
oligosaccharides in infants at the age of partial formula feeding’. The study was a double-blind,
placebo-controlled, randomised trial performed in healthy, full-term, partially breast-fed, 1 week to
3 months old, infants. A total of 82 infants were randomised to feeding with a whey formula (control
group, n = 28), a whey formula with scGOS and lcFOS (scGOS/lcFOS group, n = 27), or a whey
formula with a combination of scGOS/lcFOS and pectin-derived acidic oligosaccharides (scGOS/lcFOS/
pAOS group, n = 27). The content of sGOS, lcFOS and pAOS was 0.54, 0.06 and 0.20 g/L,
respectively. Infants were studied for the duration of the partial formula feeding period and every
2 weeks for 2 months after the cessation of breastfeeding. Outcome parameters were assessed every
2 weeks. There was no difference in the dropouts between the three groups. Primary outcomes
included total bacteria count and proportion of seven bacterial families. Secondary outcomes included
weight gain, complaints and illnesses, number and consistency of stools. There were no differences in
weight gain, stool characteristics and adverse effects between the three groups. The total bacterial
count did not alter with time or type of feeding. Compared with the control group, there was a
significant increase of the Bifidobacterium genus and a significant decrease of proportions from the
Bacteroides group and the Clostridium coccoides group in both oligosaccharidic groups. The proportion
of bifidobacteria was significantly higher in the scGOS/lcFOS/pAOs group compared with the scGOS/
lcFOS group. Because all the infants included in the study were partially breastfed during the first part
of the study period, this study does not contribute to the assessment of the safety of pectins. The
study was allocated to tier 3 in the RoB assessment.
The aim of the study of Westerbeek et al. (2010) was ‘to determine the effect of enteral
supplementation of a prebiotic mixture consisting of neutral oligosaccharides (scGOS/lcFOS) and acidic
oligosaccharides (AOS) on serious infectious morbidity in preterm infants’. The design and the
methodology of the study are described in the paper of Westerbeek et al. (2008). The study was a
randomised controlled trial performed in preterm infants (gestational age < 3 weeks and/or birth
weight < 1,500 g). A total of 114 preterm infants were randomised to enteral supplementation of 80%
scGOS/lcFOs and 20% AOS (1.5 g/kg per day) or placebo (maltodextrin) between days 3 and 30 of
life. The presence of pectins in the AOS is not mentioned explicitly in the Methods section of the 2008
and the 2010 papers from Westerbeek et al. Primary outcome was serious infectious morbidity defined
as a culture positive for sepsis, meningitis, pyelonephritis or pneumonia. Secondary outcomes during
the 80 days follow-up were feeding tolerance, days of no enteral feeding, occurrence of Bell stage II
and III necrotising enterocolitis, growth, need for mechanical ventilation, bronchopulmonary dysplasia
(BPD), retinopathy of prematurity and death. Enteral supplementation of scGOS/lcFOS/AOS did not
significantly reduce the risk of serious infectious morbidity in preterm infants. With regard to secondary
outcomes, the only significant difference between both groups was a lower incidence of mild BPD in
the supplemented group. Because of lacking information, this study does not contribute to the
assessment of the safety of pectins. The study was allocated to tier 3 in the RoB assessment.
The Panel notes the methodological limitations of above clinical studies. The Panel also notes that
all studies had a high risk of bias. The Panel considers that no conclusions can be drawn from these
clinical studies with respect to the assessment of the safety of pectins and amidated pectins.
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Other studies from the literature
The interested business operators submitted a literature study (van den Berg et al., 2016; documentation
provided to EFSA n. 2) on the effect of short-chain galacto-oligosaccharides/long-chain fructo-
oligosaccharides/pectin-derived acidic oligosaccharides (scGOS/lcFOS/pAOS) on neurodevelopmental
outcomes in infants at 24 months. The Panel considered that this study does not contribute to the
assessment of pectins andwas not further considered.
3.6.2.4. Post-marketing surveillance data
Post-marketing data were obtained from one interested business operator in the form of a
summary table of adverse events of two different companies (documentation provided to EFSA n. 3).
The first company provided data collected between January 2016 and September 2019 on pectin
containing formulae available on the market in the Bahrein, Balcans, France, Greece, KSA, South
Africa, Spain, Mexico, Italy, during which period few millions of individual items were sold. From 14
reported adverse events, the terms most often mentioned were liquid and/or frequent stools: gas
(7 events) and cutaneous reactions (3 events). The second company provided data collected from
January 2015 to September 2019 on pectin-containing products. Among several millions of individual
items sold, 114 adverse events were reported in total. Acidosis (64 events), allergic reaction
(19 events), gastrointestinal symptoms (12 events) were the most used terms to describe the events.
The Panel considered that the relationship between the events and the intake of pectin (E 440i)
and amidated pectin (E 440ii) is not confirmed and that the post-marketing surveillance data do not
show specific alerts except for the very rare symptoms of ‘allergic reaction/intolerance’.
No additional cases of adverse reactions were found by a literature search submitted by the
interested business operators (Documentation provided to EFSA n.3).
3.6.2.5. Assessment of methanol exposure
In human volunteers, consumption of 10 g (143 mg/kg bw) isolated pectin (75% methylated)
induced a significant increase in methanol in the breath and, by inference, in the blood (Lindinger
et al., 1997). Lindinger et al. (1997) calculated the amount of methanol released to be 400 mg per
adult person (5.7 mg/kg bw). In another study in human volunteers, a daily dose of 36,000 mg pectin
(equivalent to 515 mg/kg bw per day) for 6 weeks in humans was associated with only abdominal
distension and increasing flatus in some individuals. No clinically relevant health impact was found and
the level of gamma-glutamyl transferase as a marker for liver toxicity remained unchanged (Cummings
et al., 1979). In this study the dose, applying the results from the study of Lindinger et al. (1997),
would produce 20.5 mg/kg bw per day of methanol.
The extrapolation of the results from the study of Lindinger et al. (1997), assuming a degree of
methylation of 75%, to the assessment of exposure via food for infants below 16 weeks under FC
13.1.5.1 would result in an exposure of 79.7 mg/kg bw per day (for pectin exposure of 2,000 mg/kg
bw per day) and of 103.6 mg/kg bw per day (for pectin exposure of 2,600 mg/kg bw per day)
towards methanol released from pectin for infants below 16 weeks of age. The interested business
operator reported a degree of methylation between 50% and 90% for pectin (E 440i) and between
20% and 50% for amidated pectin (E 440ii). When performing the calculation with a degree of
methylation of 90% (instead of 75%), the resulting values would be 15% higher (91.6 mg/kg bw per
day and 119.1 mg/kg bw per day). This exposure could lead to adverse health effects. Blindness in
human may occur, as reported, at doses as low as 214 mg/kg bw as a single acute dose (US EPA –
Integrated Risk Information System22) and 260 mg/kg by the ECHA Committee for risk assessment in
2015. Metabolic acidosis is another health impairment which becomes relevant at doses between 100
and 150 mg/kg bw per day (Ashurst and Nappe, 2020). A derived no effects level (DNEL) of 88 mg/kg
bw (based on methanol ocular toxicity, i.e. blindness in humans) was set by the ECHA Committee for
risk assessment (RAC) in 2015 for adults (ECHA Committee for risk assessment, 2015). The
Panel noted that the intake of pectins will not be as a single bolus dose but in divided doses over the
day. However, because of the lack of data on the formation and the kinetics of methanol and also on
the effect duration, the Panel has to take the bolus dose in adult as the reference point.
22 https://web.archive.org/web/20121205004930/http://www.epa.gov/iris/subst/0305.htm, accessed on 28/10/2020.
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3.6.2.6. Assessment of formaldehyde exposure
The Panel assumed that all methanol was converted into formaldehyde, which then formed a
formaldehyde acetal with water. Concerning the metabolic conversion by aldehyde dehydrogenase,
there are data in infants showing that the enzyme activity is the same as in adult (Schippan et al.,
1975). The increase in formaldehyde acetal associated with 91.6 mg/kg per day methanol given as a
single dose (the Panel noted that this was an unlikely scenario for dietary pectin) would result in an
increase of nearly 70% (for the steady state level) of the normal intracellular endogenous
formaldehyde level (EFSA ANS Panel, 2013).
This can be used to make an estimate of the additional burden of formaldehyde acetal associated
with the intake of pectin. Such an additional burden should be evaluated in the light of the naturally
occurring interspecies and intraspecies variation in the internal level of formaldehyde and
formaldehyde acetal. Kleinnijenhuis et al. (2013) using a sensitive and specific method have measured
a formaldehyde concentration in blood of 2.25  0.67 (mean  SD) mg/L in rats. This corresponds to
a coefficient of variation of 30% in endogenous formaldehyde blood levels in rats (EFSA ANS Panel,
2013). Hence, the additional burden of formaldehyde due to methanol formed by release from pectin
with a degree of methylation of 90% in infants below 16 weeks of age is above the upper end of the
natural range.
3.7. Discussion
Analytical data on toxic elements were provided by one interested business operator for levels of
arsenic, lead, cadmium, mercury and aluminium in commercial pectin (E 440i) and amidated pectin
(E 440ii) samples in response to the call of data (documentation provided to EFSA n. 1). The
Panel noted that the analytical data on the toxic metals provided for the 29 independent commercial
E440i and E440ii samples are substantially lower than the lowest technically achievable levels proposed
by the business operator.
Microbiological data on viable count, yeasts including osmophilic yeasts, moulds including xerophilic
moulds, E. coli and Salmonella spp. were provided for 7 batches of (E 440i) and 6 batches for (E 440ii)
(documentation provided to EFSA n. 1). The Panel noted that the analytical data submitted for the
total aerobic plate count and the total yeast and mould count are substantially lower than the
respective proposed lowest technically achievable values by the business operator. Furthermore, the
Panel noted that the statement of the business operator whereupon Cronobacter sakazakii
(documentation provided to EFSA n. 3,4) are eliminated during the production process is not
supported by analytical data, as no results nor lowest technically achievable values were provided. The
information on fate and reaction products of pectins in finished products provided by the business
operators is very general and not supported by representative analytical data.
Concerning the toxic elements, the potential exposure from the consumption of E 440 could be
substantial. In the case of lead and cadmium in infant formulae, the food additive specification values
are not consistent with Reg. (EC) No 1881/200623 (see Appendix D). The Panel noted that the MOS/
MOE for arsenic and lead are very low. For arsenic the reference point is based on carcinogenicity for
which the MOS/MOE should be at least 10,000 (EFSA, 2005). For lead, the reference point is based on
a study demonstrating perturbation of intellectual development in children with the critical response
size of 1 point reduction in IQ. In the Opinion on lead (EFSA CONTAM Panel, 2010), it is mentioned
that a 1 point reduction in IQ is related to a 4.5% increase in the risk of failure to graduate from high
school and that a decrease of 1 IQ in children can be associated with a decrease of later productivity of
about 2%. A risk cannot be excluded if the exposure exceeds the BMDL01 (MOS/MOE lower than 1).
The Panel considered feasible to amend the EU specifications based on the information submitted
in response to the call for data. This refers to lowering existing limits for toxic elements (arsenic, lead,
cadmium, mercury) and sulfur dioxide and to include limits for aluminium and microbiological criteria
(including Cronobacter (Enterobacter) sakazakii) for the food additive (see Table 11).
No new data were provided concerning ADME, acute toxicity, short-term and subchronic toxicity,
genotoxicity, chronic toxicity and carcinogenicity and reproductive and developmental toxicity.
Two 21-day feeding studies in neonatal piglets available to the Panel were allocated to tier 1 in the
risk of bias (RoB) assessment (low risk of bias). In these studies, the piglets received a milk replacer
formula containing pectins in concentrations of 0, 0.5, 3 and 10 g/L or 0, 2 and 10 g/L, respectively.
23 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in
foodstuffs (Text with EEA relevance) OJ L 364, 20.12.2006, p. 5–24.
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No adverse effects on body weight, feed intake clinical parameters (haematology, clinical chemistry
and urinalysis) and post mortem organ weights and gross and histopathology up to 3 g pectins/L in
the first study and on body weight and feed intake at 2 g pectins/L in the second study were
observed. These concentrations corresponded to 1,069 and 704 mg pectins/kg bw per day,
respectively. The data were not suitable to perform BMD modelling. Due to the dose spacing and the
broader selection of toxicologically relevant endpoints, the Panel considered that the NOAEL for pectin
was 1,069 mg /kg bw per day.
Seven publications of clinical studies were submitted by the interested business operator. The
composition of the tested formulas was not available neither from the publications nor provided from
the interested business operators. Only the content of pectins was provided and in addition the
information on the presence of other thickeners in the formulas. The Panel noted that none of the
formulas did contain pectins as the only source for thickening but additional locust bean gum (5
formulas) or xanthan gum (3 formulas). The clinical studies were assessed with respect to their RoB
and all were allocated to tier 3 (high risk of bias) see Appendix C. The Panel notes the methodological
limitations of the clinical studies, in particular the absence of randomisation and the fact that in none
of the studies pectin and amidated pectins (E 440i, E 440ii) were the only thickeners used so that the
results cannot be attributed to these food additives. Furthermore, most of the studies are studies
without a control group precluding any conclusions to be drawn. Because of the limitations the
Panel considers that the studies cannot support the assessment of the safety of pectin and amidated
pectin (E 440i, E 440ii).
Furthermore, publications with pectin-derived acidic oligosaccharides were reviewed by the
Panel and assigned a tier 3 (high risk of bias). These studies did not provide any relevant information
for the risk assessment of pectins as a food additive.
The Panel considered that the post-marketing surveillance data do not show specific alerts except
for the very rare symptoms of ‘allergic reaction/intolerance’.
Dietary exposure to pectins (E 440) from their uses as food additives was assessed based on (1)
MPLs set out in the EU legislation (defined as the regulatory maximum level exposure assessment
scenario) and (2) the reported use levels (defined as the refined exposure assessment scenario).
For infants below 16 weeks of age, both scenarios are based on the recommended consumption
levels from SC Guidance (EFSA Scientific Committee, 2017) which recommends values of 200 and 260
mL formula/kg bw per day as conservative mean and high-level consumption values for 14- to 27-day-
old infants. For infants below 16 weeks of age consuming FSMP (FC 13.1.5.1), mean exposure to
pectins (E 440) in the regulatory maximum level exposure assessment scenario was estimated at 2,000
mg/kg bw per day while at the high level was estimated at 2,600 mg/kg bw per day. Using the
maximum level reported by industry, exposure estimates for pectins (E 440) were estimated at 834
mg/kg bw per day at the mean and at 1,084 mg/kg bw per day at the high level. For the scenario
using the mean of the reported use levels from industry, exposure estimates for pectins (E 440) were
of 693 mg/kg bw per day at the mean and 901 mg/kg bw per day at the high level of consumption.
For infants above 16 weeks of age and toddlers consumers of foods for special medical purposes,
mean dietary exposure to pectins (E 440) ranged from 9 mg/kg bw per day in toddlers to 434 mg/kg
bw per day in infants above 16 weeks of age. At the high level (95th percentile), dietary exposure to
pectins (E 440) ranged from 30 mg/kg bw per day up to 1,263 mg/kg bw per day in infants above 16
weeks of age.
The Panel decided to base its safety assessment on the MOS calculated for the different age groups
and different scenarios. Due to the low internal validity of the clinical studies and further flaws, the
Panel concluded that a reference point could not be derived from them. The Panel noted that the
results of the piglet study with pectin could serve to derive a reference point for pectins (E 440i, ii).
Which would be the NOAEL of 1,069 mg pectins/kg bw per day.
With a NOAEL of 1,069 mg pectin/kg bw per day and an exposure in the regulatory maximum level
exposure assessment scenario for pectins (E 440) of 2,000 mg/kg bw per day (mean consumption)
and 2,600 mg/kg bw per day (high level consumption) the MOS is below 1. The MOS is above 1 (1.3)
when maximum use level reported by industry of 834 mg/kg bw per day (mean consumption) and
below 1 when maximum use level reported by industry of 1,084 mg/kg bw per day (high level
consumption) are used as estimates for the exposure. The MOS is higher than 1 with mean use level
reported by industry of 693 mg/kg bw per day (mean consumption) and with high-level consumption
of 901 mg/kg bw per day (1.5 and 1.2, respectively). This assessment is valid for infants below 16
weeks consuming FSMP (FC 13.1.5.1).
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For infants above 16 weeks of age consuming FSMP according to FC 13.1.5.1. and FC 13.1.5.2, the
MOS calculations gave the following results:
– for toddlers (12–35 months) the MOS is between 119 and 4 using the mean dietary exposure
to pectins (E 440i,ii) and 26 and 1.6 at the high level (95th percentile) of dietary exposure to
pectins (E 440i,ii), respectively;
– for infants (16 weeks to 11 months) the MOS ranged from 107 and 2.5 using the mean
dietary exposure to pectins (E 440i,ii) and between 36 and 0.8 at the high level (95th
percentile) of dietary exposure to pectins (E 440i,ii).
The Panel concluded that an MOS below 1 is too low. It is noted that the exposure estimates are
considered not an overestimation but realistic (see Section 3.4.3). JECFA (JECFA, 2015) considered
that an MOS in the region of 1–10 could be interpreted as low risk for the health of infants aged 0–12
weeks for a thickener like starch.
The maximum use levels proposed by industry to JECFA in 2016 (JECFA, 2016a, 2017) for uses in
infant formula and formula for special medical purposes intended for infants of 0.2% would result in
an MOS above 1 for all exposure scenarios. Because a neonatal piglet model has been used avoiding
the need for an additional inter species uncertainty factor, the proposed maximum use level of 0.2%
would not be of safety concern.
The Panel further noted that for combinations of pectins (E 440) with other thickeners which seem
to be on the market no studies in an appropriate animal model are available. The clinical studies
presented by interested business operators have a low internal validity; most of them are uncontrolled
studies.
Consumption of pectin (75% methylated) induced a significant increase in methanol in the breath
and, by inference, in the blood (Lindinger et al., 1997). At the dose of 10 g, the lowest amount of
methanol released is 400 mg per adult person (5.7 mg/kg bw). The extrapolation of these results to
the assessment of exposure via foods for infants below 16 weeks of age under FC 13.1.5.1 (see
Section 3.4.1) would result in an exposure of 79.7 mg/kg bw per day (for pectin exposure of 2,000
mg/kg bw per day) and of 103.6 mg/kg bw per day (for pectin exposure of 2,600 mg/kg bw per day)
towards methanol released from pectin in infants below 16 weeks of age. Although the flora of
gastrointestinal tract is not fully comparable in the first days of life to that of the adult, after birth the
microbiome of the newborn infants becomes similar to that of the mother (B€ackhed et al., 2015). The
interested business operators reported a degree of methylation between 50% and 90% for pectin
(E 440i) and between 20% and 50% for amidated pectin (E 440ii). When performing the calculation
with a degree of methylation of 90% (instead of 75%), the resulting values would be 15% higher
(91.6 mg/kg bw per day and 119.4 mg/kg bw per day). This exposure could lead to adverse health
effects. Blindness in human may occur, as reported, at doses as low as 214 mg/kg bw as a single
acute dose (US EPA- Integrated Risk Information System) and 260 mg/kg by the ECHA Committee for
risk assessment in 2015. Metabolic acidosis is another health impairment which becomes relevant at
doses between 100 and 150 mg/kg bw per day (Ashurst and Nappe, 2020). A derived no effects level
(DNEL) of 88 mg/kg bw (based on methanol ocular toxicity, i.e. blindness in humans) was set by the
ECHA Committee for risk assessment (RAC) in 2015 for adults (ECHA Committee for risk assessment,
2015). When the maximum use level provided by industry are considered, the exposure to methanol
via foods for infants below 16 weeks of age under FC 13.1.5.1 would result in an exposure of 43.2
mg/kg bw per day (for pectin exposure of 1,084 mg/kg bw per day, 95th percentile) towards methanol
released from pectin. The Panel considered this as a conservative approach also noting that the intake
of pectins will not be as a single bolus dose but in divided doses over the day.
For infants above 16 weeks of age, the exposure towards methanol is estimated to be roughly 50%
of that for the infants below 16 weeks of age.
4. Conclusions
• Due to the low internal validity of the clinical studies, the Panel concluded that a reference
point could not be derived from them, but the results of the adequate piglet study could serve
to derive a reference point. When calculating the MOS for pectins exposure, this was below 1
for some scenarios. The Panel concluded that an MOS below 1 is too low.
• Under the current exposure estimates at the MPLs, an internal methanol exposure (in the
range of methylation given for pectin (E 440i)) would result that could lead to adverse health
effects in infants below 16 weeks of age.
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• The Panel concluded that the risk assessment for toxic elements clearly indicates the need to
decrease the current maximum limits for arsenic, lead, cadmium, mercury and sulfur dioxide
and to set a maximum limit for aluminium in pectins (E 440i and E 440ii), considering also
other sources of exposure to these toxic elements.
• Because of both the botanical origin and the polysaccharidic nature of pectins (E 440i, ii), they
can be a substrate of microbiological contamination. Therefore, the Panel noted that




• The European Commission to consider revising the current specifications for the food additive
pectin (E 440i) and amidated pectin (E 440ii) in line with the proposals made on the basis of
the information provided and based on the considerations of the Panel, see Table 11.
• The European Commission to consider lowering the MPL of pectin (E 440i) and amidated
pectin (E 440ii) in FCs 13.1.5.1 and 13.1.5.2, in order to reduce the exposure to both the
additives themselves and to methanol.
6. Documentation as provided to EFSA
1) International Pectin Producers Association (IPPA), 2019. Submission of data in response to the
call for technical and toxicological data on pectin (E 440i) and amidated pectin (E 440ii) for
uses as a food additive in foods for all population groups including infants below 16 weeks of
age. Submitted on December 2019.
2) International Pectin Producers Association (IPPA), 2020. Clarification on the submission of
data in response to the call for technical and toxicological data on pectin (E 440i) and
amidated pectin (E 440ii) for uses as a food additive in foods for all population groups
including infants below 16 weeks of age. Submitted on August 2020.
3) Specialised Nutrition Europe, 2019. Submission of data in response to the call for technical
and toxicological data on pectin (E 440i) and amidated pectin (E 440ii) for uses as a food
additive in foods for all population groups including infants below 16 weeks of age. Submitted
on December 2019.
4) Specialised Nutrition Europe, 2020. Clarifications on the submission of data in response to the
call for technical and toxicological data on pectin (E 440i) and amidated pectin (E 440ii) for
uses as a food additive in foods for all population groups including infants below 16 weeks of
age. Submitted on September 2020.
5) Specialised Nutrition Europe, 2020. Clarifications on the submission of data in response to the
call for technical and toxicological data on pectin (E 440i) and amidated pectin (E 440ii) for
uses as a food additive in foods for all population groups including infants below 16 weeks of
age. Submitted on November 2020.
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Abbreviations
ADI acceptable daily intake
ADME absorption, distribution, metabolism, excretion
ANS Panel EFSA Panel on Food Additives and Nutrient Sources added to Food
bw body weight
CAS Chemical Abstract Service
CFU Colony-forming unit
FAF Panel Panel on Food Additives and Flavourings
FAO/WHO Food and Drug Organisation/World Health Organisation
FC Food category
FSMP Food for special medical purposes
JECFA Joint FAO/WHO Expert Committee on Food Additives
Mintel GNPD Mintel’s Global New Products Database
MOE margin of exposure
MOS margin of safety
MPL maximum permitted levels
NOAEL no-observed-adverse-effect level
NOEL no-observed-effect level
SC Scientific Committee of EFSA
SCF Scientific Committee on Food
TAMC total anaerobic microbial count
TYMC total combined yeast and mould count
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Appendix A – Data requested in the call for data (Call for technical and
toxicological data on pectins (E 440i,ii) for uses as a food additive in foods
for all population groups including infants below 16 weeks of age24






A. Information regarding the follow-up of the conclusions and the recommendations of the EFSA
ANS Panel opinion on the safety of pectins (E 440i,ii) as food additive
1. Technical
data
• Analytical data on current levels of arsenic, lead,
cadmium, mercury and aluminium in commercial
samples of the food additives;
• the lowest technologically achievable level for
lead, mercury, cadmium, arsenic and aluminium in
order to adequately define their maximum limits in
the specifications;
• Because of both the botanical origin and the
polysaccharidic nature of pectin, they can be a
substrate of microbiological contamination. Data
should be provided demonstrating the absence of
Salmonella spp. and Escherichia coli and on the
lowest total aerobic microbial count (TAMC) and
total combined yeast and mould count (TYMC)





According to the conclusions and recommendations in
the Scientific opinion on the re-evaluation of pectin
(E 440i) and amidated pectin (E 440ii) as a food
additives by the EFSA ANS Panel published in 2017,
the generation of additional data to assess the
potential health effects of pectin (E 440i) and
amidated pectin (E 440ii) when used as a food
additive in ‘dietary foods for infants for special medical
purposes and special formulae for infants’ (Food
category 13.1.5.1) and in ‘dietary foods for babies and
young children for special medical purposes as defined
in Directive 1999/21/EC’ (Food category 13.1.5.2) was
recommended. These requirements could be







Literature searches should be conducted relevant for
the safety evaluation of pectin (E 440i) and amidated
pectin (E 440ii) for all uses in foods for all population
groups from 12/10/2016 up to the date of the data
submission, as described in the Guidance for




24 Available online: https://www.efsa.europa.eu/en/consultations/call/call-technical-and-toxicological-data-pectin-e440i-and-amida
tedand responses from interested business operators.
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B. Information required for the risk assessment of pectins (E 440i,ii) as food additive for use in
foods for infants below 16 weeks of age
1. Technical
data
• Information on the usage levels of pectin (E 440i)
and amidated pectin (E 440ii), alone or in
combination with other thickening agents
(indication of food additive name and level of use)
in the special formulae for infants below 16 weeks
of age under special medical conditions (FC
13.1.5.1);
• Information on the fate and the reaction products
pectin (E 440i) and amidated pectin (E 440ii) in
the special formulae for infants below 16 weeks of
age under special medical conditions (FC
13.1.5.1);
• Information on particular specification
requirements for identity and purity of pectin
(E 440i) and amidated pectin (E 440ii) (e.g.
content of toxic elements. methanol, ethanol,
propan-2-ol, sulfur oxide) in the special formulae
for infants below 16 weeks of age under special
medical conditions (FC 13.1.5.1). Analytical data
on impurities in the final special formulae for
infants below 16 weeks of age need to be
provided when no legal limit has been established.
In addition, data should be provided






• The full reports of the repeated dose studies in
neonatal piglets (Dilger, 2015; MPI, 2013);
• clinical data focusing on gastrointestinal effects to
assess the safety of pectin (E 440i) and amidated
pectin (E 440ii) as food additives when used in
‘dietary foods for special medical purposes and
special formulae for infants’ (FC 13.1.5.1);
• post-marketing surveillance reports on undesired
and adverse reactions, indicating the ages and
other relevant data of the exposed infants and
young children and the use levels of pectin
(E 440i) and amidated pectin (E 440ii) in the
marketed products;
• published and unpublished case reports (e.g.
available nutrivigilance data) on undesired and
adverse effects, including e.g. flatulence,
gastrointestinal discomfort, changes of stool-
frequencies and -consistency, diarrhoea and
allergic reactions, associated with the oral
administration of pectin (E 440i) and amidated






Literature searches should be conducted relevant for
the safety evaluation of pectin (E 440i) and amidated
pectin (E 440ii) when used in foods for infants below
16 weeks of age up to the date of the data
submission, as described in the Guidance for
submission for food additive evaluations (Section 5.3).
Received Assessed, no
further follow-up
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Appendix B – Risk of bias/Internal validity for Experimental Animal Studies
(modified from to NTP-OHAT, 2015, 2019)
The ratings of the key and non-key questions (++, +, –, ) will be integrated to classify the
studies in tiers from 1 to 3 corresponding to decreasing levels of internal validity.
Tier 1:
• All the key questions are scored +/++
AND
• No more than one non-key question is scored –
AND
• No non-key question is scored –
Tier 2:
• All the other combinations not falling under tier 1 or 3
Tier 3:
• Any question is scored – –
OR
• More than one key question is scored –






question also on F1
and F2 generation)
Key question
Selection ++ if the method is described and it is adequate
+ if the authors only indicate that randomisation was
done but do not describe the method
– no mentioning of randomisation
 direct evidence of no randomisation




Selection ++ properly concealed and described how
concealment was performed
+ mentioning that concealment was performed; + is
also appropriate if non-concealment does not
influence the outcome
– if non-concealment does influence the outcome
(measurements with a subjective part (e.g.
preparation of fat pads, observation of behaviour)
 if non-concealment does influence the outcome






Performance ++ experimental conditions described and identical
across study groups (feeding, water supply, bedding,
day/night cycle; temperature; humidity)
+ incomplete description of experimental conditions;
+ is also appropriate if lack of information does not
influence the outcome
– if lack of information does influence the outcome
 if factors clearly indicate that treatment
conditions were different does influence the outcome
to a very important part
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Number Question Domain of bias Rating (++, +, –, )
4* Was the research
personnel blinded
to the study group?
Key question
Performance ++ if there is direct evidence that the research
personnel did not know what group animals were
allocated to, and it is unlikely that they could have
broken the blinding of allocation
+ if not reported and lack of adequate allocation
concealment would not appreciably affect the
allocation of animals to different study groups (e.g.
methods used which do not have a subjective
component)
– if not reported and lack of adequate allocation
concealment would appreciably affect the allocation
of animals to different study groups (e.g. methods
used which have a subjective component)
 if there is direct evidence that it was possible for
the research personnel to know what group animals
were allocated to, or it is likely that they could have
broken the blinding of allocation





Attrition/exclusion ++ There is direct evidence that loss of animals was
adequately addressed and reasons were documented
when animals were removed from a study.
OR
Missing data have been imputed using appropriate
methods (ensuring that characteristics of animals are
not significantly different from animals retained in
the analysis).
+ There is indirect evidence that loss of animals was
adequately addressed, and reasons were
documented when animals were removed from a
study.
OR
It is deemed that the proportion lost would not
appreciably bias results. This would include reports
of no statistical differences in characteristics of
animals removed from the study from those
remaining in the study.
OR
There is insufficient information provided about loss
of animals (record ‘NR’ as basis for answer) but it is
considered that this does not have an impact on the
validity of the study.
– There is indirect evidence that loss of animals was
unacceptably large and not adequately addressed
(e.g. if unexplained loss is equal or more than 25%).
OR
There is insufficient information provided about loss
of animals (record ‘NR’ as basis for answer) and it is
suspected that this would have an impact on the
validity of the study.
Note: Unexplained inconsistencies between materials
and methods and results sections (e.g.
inconsistencies in the numbers of animals in different
groups) could be an example of indirect evidence.
 There is direct evidence that loss of animals was
unacceptably large and not adequately addressed.
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Number Question Domain of bias Rating (++, +, –, )





Detection ++ There is direct evidence that the substance was
sufficiently described and consistently administered
(e.g. with the same method and timeframe) across
treatment groups.
+ There is indirect evidence that the substance was
sufficiently described and consistently administered
(i.e. with the same method and time-frame) across
treatment groups.
OR
There is insufficient information provided about
description and administration of the substance
(record ‘NR’ as basis for answer) but it is considered
that this does not have an impact on the validity of
the study.
– There is indirect evidence that the substance was
not sufficiently described and was not consistently
administered (e.g. with the same method and
timeframes) across groups.
OR
There is insufficient information provided about
description and administration of the substance
(record ‘NR’ as basis for answer) and it is suspected
that this has an impact on the validity of the study.
 There is direct evidence that the substance was
not sufficiently described and/or was not consistently
administered (e.g. with the same method and
timeframes) across groups.








assessed at the same
length of time (i.e. day
and/or time of day)














Was the number of
animals per dose
group appropriate?
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Number Question Domain of bias Rating (++, +, –, )
Element 4
Was the number of
animals per sex in
each cage appropriate
for the study type and
animal model?
Element 5















time points in order to
generate sensitive,
valid and reliable data?




Selective reporting ++ There is direct evidence that all of the study’s
measured outcomes (apical and intermediate)
outlined in the protocol, methods, abstract, and/or
introduction that are relevant for the evaluation have
been reported.
This would include outcomes reported with sufficient
detail to be included in meta-analysis or fully
tabulated during data extraction and analyses had
been planned in advance.
+ There is indirect evidence that all of the study’s
measured outcomes (apical and intermediate)
outlined in the protocol, methods, abstract, and/or
introduction that are relevant for the evaluation have
been reported. This would include outcomes
reported with insufficient detail such as only
reporting that results were statistically significant (or
not).
OR
Analyses that had not been planned in advance (i.e.
retrospective unplanned subgroup analyses) are
clearly indicated as such and it is deemed that the
unplanned analyses were appropriate and selective
reporting would not appreciably bias results (e.g.
appropriate analyses of an unexpected effect).
OR
There is insufficient information provided about
selective outcome reporting (record ‘NR’ as basis for
answer) but it is considered that this does not have
an impact on the validity of the study.
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Number Question Domain of bias Rating (++, +, –, )
– There is indirect evidence that all of the study’s
measured outcomes (apical and intermediate)
outlined in the protocol, methods, abstract and/or
introduction that are relevant for the evaluation have
not been reported.
OR
There is indirect evidence that unplanned analyses
were included that may appreciably bias results.
OR
There is insufficient information provided about
selective outcome reporting (record ‘NR’ as basis for
answer) and it is suspected that this has an impact
on the validity of the study.
Note: Unexplained inconsistencies between materials
and methods and results/abstract or summary
sections (e.g. inconsistencies in the numbers of
animals in different groups) could be an example of
indirect evidence.
 There is direct evidence that not all of the
study’s measured outcomes (apical and intermediate)
outlined in the protocol, methods, abstract, and/or
introduction that are relevant for the evaluation have
not been reported.
In addition to not reporting outcomes, this would
include reporting outcomes based on composite
score without individual outcome components or
outcomes reported using measurements, analysis
methods or subsets of the data that were not pre-
specified or reporting outcomes not pre-specified, or





Other sources of bias ++ There is direct evidence that the statistical
methods seem appropriate and were clearly reported
(adequate treatment of multiple testing).
+ Statistical methods were not clearly reported but it
may be inferred from other information that they
were appropriate.
OR
There is insufficient information provided about
statistical methods (record ‘NR’ as basis for answer),
but it is considered that this does not have an impact
on the validity of the study.
 Statistical methods were not clearly reported, but
it may be inferred from other information that they
were not appropriate.
OR
There is insufficient information provided about
statistical methods (record ‘NR’ as basis for answer)
and it is suspected that this has an impact on the
validity of the study.
– There is direct evidence that the statistical
methods applied were inappropriate.
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Appendix C – Risk of bias/Internal validity for the clinical studies
(modified from to NTP-OHAT, 2015, 2019)
C.1. Decision rules
The ratings of the key and non-key questions (++, +, –, ) will be integrated to classify the
studies in tiers from 1 to 3 corresponding to decreasing levels of internal validity.
Tier 1:
• All the key questions are scored +/++
AND
• No more than one non-key question is scored –
AND
• No non-key question is scored –
Tier 2:
• All the other combinations not falling under tier 1 or 3
Tier 3:
• Any question is scored –
OR
• More than one key question is scored –
Elements considered in the assessment







++ There is direct evidence that subjects (or clusters) were allocated to any
study group including controls using a method with a random component.
Acceptable methods of randomisation include referring to a random number
table, using a computer random number generator, coin tossing, shuffling
cards or envelopes, throwing dice, or drawing of lots (Higgins and Green,
2011). Restricted randomisation (e.g. blocked randomisation) to ensure
particular allocation ratios will be considered low risk of bias. Similarly,
stratified randomisation and minimisation approaches that attempt to
minimise imbalance between groups on significant prognostic factors (e.g.
body weight) will be considered acceptable.
+ There is indirect evidence that subjects (or clusters) were allocated to study
groups using a method with a random component (i.e. authors state that
allocation was random, without description of the method used).
OR
It is deemed that allocation without a clearly random component during the
study would not appreciably bias results. For example, approaches such as
biased coin or urn randomisation, replacement randomisation, mixed
randomisation and maximal randomisation may require consultation with a
statistician to determine risk-of-bias rating (Higgins and Green, 2011).
NR There is insufficient information provided about how subjects (or clusters)
were allocated to study groups.
– There is indirect evidence that subjects (or clusters) were allocated to study
groups using a method with a non-random component.
NOTE: Non-random allocation methods may be systematic but have the
potential to allow participants or researchers to anticipate the allocation to
study groups. Such ‘quasi-random’ methods include alternation, assignment
based on date of birth, case record number, or date of presentation to
study.
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Question Rating Explanation for expert judgement
– There is direct evidence that subjects (or clusters) were allocated to study
groups using a non-random method including judgement of the clinician,
preference of the participant, the results of a laboratory test or a series of





++ There is direct evidence that at the time of recruitment the research
personnel and subjects did not know what study group subjects were
allocated to, and it is unlikely that they could have broken the blinding of
allocation until after assignment was complete and irrevocable. Acceptable
methods used to ensure allocation concealment include central allocation
(including telephone, web-based and pharmacy-controlled randomisation);
sequentially numbered drug containers of identical appearance; sequentially
numbered, opaque, sealed envelopes; or equivalent methods.
+ There is indirect evidence that the research personnel and subjects did not
know what study group subjects were allocated to and it is unlikely that
they could have broken the blinding of allocation until after recruitment was
complete and irrevocable.
OR
It is deemed that lack of adequate allocation concealment would not
appreciably bias results (e.g. some crossover designs).
NR There is insufficient information provided about allocation to study groups.
– There is indirect evidence that at the time of recruitment it was possible for
the research personnel and subjects to know what study group subjects
were allocated to, or it is likely that they could have broken the blinding of
allocation before assignment was complete and irrevocable.
NOTE: Inadequate methods include using an open random allocation
schedule (e.g. a list of random numbers); assignment envelopes used
without appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation; date of birth;
case record number; or any other explicitly unconcealed procedure. For
example, if the use of assignment envelopes is described, but it remains
unclear whether envelopes were sequentially numbered, opaque and sealed.
– There is direct evidence that at the time of recruitment it was possible for
the research personnel and subjects to know what study group subjects
were allocated to, or it is likely that they could have broken the blinding of







++ There is direct evidence that the subjects and research personnel were
adequately blinded to study group, AND it is unlikely that they could have
broken the blinding during the study. Methods used to ensure blinding
include central allocation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed envelopes; or
equivalent methods.
+ There is indirect evidence that the subjects and research personnel were
adequately blinded to study group, AND it is unlikely that they could have
broken the blinding during the study.
OR
There is direct evidence for no blinding during the study (including where it
was not possible to implement) AND it is deemed that no blinding would
appreciably bias results BUT bias minimising measures have been
adequately implemented.
OR
It is deemed that lack of adequate blinding or no blinding during the study
would not appreciably bias results (e.g. controls unlikely to behave
differently for factors other than sodium intake) (e.g. cross-over).
NR There is insufficient information provided about blinding to study group
during the study (including possible breaking and minimising measures).
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Question Rating Explanation for expert judgement
– There is indirect evidence that it was possible for research personnel or
subjects to infer the study group AND it is deemed that lack of adequate
blinding or no blinding during the study would appreciably bias results (e.g.
no comparable treatment of controls, including not comparable exposure to
factors other than the interventions of interest; differential behaviour) AND
no bias minimising measures have been adequately implemented.
– There is direct evidence for lack of adequate blinding of the study group
(including no blinding or incomplete blinding) of research personnel and
subjects AND it is deemed that lack of adequate blinding or no blinding
during the study would appreciably bias results (e.g. no comparable
treatment of controls, including not comparable exposure to factors other
than the interventions of interest, differential behaviour) AND no bias







++ There is direct evidence that there was no loss of subjects during the study
and outcome data were complete.
OR
Loss of subjects (i.e. incomplete outcome data) was adequately addressed
and reasons were documented when human subjects were removed from a
study or analyses. Review authors should be confident that the participants
included in the analysis are exactly those who were randomised into the
trial. Acceptable handling of subject attrition includes: very few missing
outcome data (e.g. less than 10% in each group (Genaidy et al., 2007))
AND reasons for missing subjects unlikely to be related to outcome (for
survival data, censoring unlikely to be introducing bias) AND missing
outcome data balanced in numbers across study groups, with similar
reasons for missing data across groups (i.e. unlikely to be related to
exposure).
OR
Analyses (such as intention-to-treat analysis) in which missing data have
been imputed using appropriate methods (ensuring that the characteristics
of subjects lost to follow up or with unavailable records are described in
identical way and are not significantly different from those of the study
participants).
NOTE: Participants randomised but subsequently found not to be eligible
need not always be considered as having missing outcome data) (Higgins
and Green, 2011).
+ There is indirect evidence that loss of subjects (i.e. incomplete outcome
data) was adequately addressed and reasons were documented when
human subjects were removed from a study.
OR
It is deemed that the proportion lost to follow-up would not appreciably
bias results (e.g. less than 20% in each group in parallel studies (Genaidy
et al., 2007)). This would include reports of no statistical differences in
characteristics of subjects lost to follow up or with unavailable records from
those of the study participants. Generally, the higher the ratio of
participants with missing data to participants with events, the greater
potential there is for bias. For studies with a long duration of follow-up,
some withdrawals for such reasons are inevitable.
NB: For crossover designs, this may be less of an issue.
NR There is insufficient information provided about numbers of subjects lost to
follow-up.
– There is indirect evidence that loss of subjects (i.e. incomplete outcome
data) was unacceptably large (e.g. greater than 20% in each group in
parallel studies (Genaidy et al., 2007)) and not adequately addressed.
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Question Rating Explanation for expert judgement
– There is direct evidence that loss of subjects (i.e. incomplete outcome data)
was unacceptably large and not adequately addressed (e.g. greater than
20% in each group in parallel studies (Genaidy et al., 2007)). Unacceptable
handling of subject attrition includes: reason for missing outcome data likely
to be related to true outcome, with either imbalance in numbers or reasons
for missing data across study groups (i.e. likely to be related to the
exposure); or potentially inappropriate application of imputation.





++ There is direct evidence that the exposure (including compliance with the
treatment, if applicable) was independently characterised
AND that exposure was consistently administered (i.e. with the same
method and time-frame) across treatment groups.
+ There is indirect evidence that the exposure (including compliance with the
treatment, if applicable) was independently characterised
AND there is indirect evidence that exposure was consistently administered
(i.e. with the same method and time-frame) across treatment groups.
NR There is insufficient information provided to judge the exposure
characterisation
– There is indirect evidence that the exposure (including compliance with the
treatment, if applicable) was assessed using poorly validated methods (e.g.
FFQs, spot urine etc.).
OR
There is indirect evidence that the exposure assessment was probably
biased.
– There is direct evidence that the exposure (including compliance with the
treatment, if applicable) was assessed using poorly validated methods (e.g.
FFQs, spot urine etc.).
OR
There is direct evidence that the exposure assessment was biased.





++ There is direct evidence that the outcome was assessed using well-
established methods (e.g. for office BP: according to a clearly described
methodology, including e.g. repeated measurements per visit, trained
technician, resting period before each measurement).
AND
There is direct evidence that the outcome assessors were adequately
blinded to the study group, and it is unlikely that they could have broken
the blinding prior to reporting outcomes.
+ There is indirect evidence that the outcome was assessed using acceptable
methods (i.e. deemed valid and reliable but not the gold standard) OR it is
deemed that the outcome assessment methods used would not appreciably
bias results.
AND
There is indirect evidence that the outcome assessors were adequately
blinded to the study group, and it is unlikely that they could have broken
the blinding before reporting outcomes OR it is deemed that lack of
adequate blinding of outcome assessors would not appreciably bias results.
NR There is insufficient information provided about blinding of outcome
assessors or the method of measurement.
– There is indirect evidence that the outcome assessment method is an
unacceptable method.
OR
There is indirect evidence that it was possible for outcome assessors to
infer the study group before reporting outcomes.
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Question Rating Explanation for expert judgement
– There is direct evidence that the outcome assessment method is an
unacceptable method.
OR
There is direct evidence for lack of adequate blinding of outcome assessors





++ There is direct evidence that all of the study’s measured outcomes (primary
and secondary) outlined in the protocol, methods, abstract and/or
introduction (that are relevant for the evaluation) have been reported.
+ There is indirect evidence that all of the study’s measured outcomes
(primary and secondary) outlined in the methods, abstract and/or
introduction (that are relevant for the evaluation) have been reported.
OR
Analyses that had not been planned in advance (i.e. retrospective
unplanned subgroup analyses) are clearly indicated as such and it is
deemed that the unplanned analyses were appropriate and selective
reporting would not appreciably bias results (e.g. appropriate analyses of
an unexpected effect). This would include outcomes reported with
insufficient detail such as only reporting that results were statistically
significant (or not).
NR There is insufficient information provided about selective outcome
reporting.
– There is indirect evidence that all of the study’s measured outcomes
(primary and secondary) outlined in the methods, abstract and/or
introduction (that are relevant for the evaluation) have not been reported.
OR
There is indirect evidence that unplanned analyses were included that may
appreciably bias result.
– There is direct evidence that all of the study’s measured outcomes (primary
and secondary) outlined in the methods, abstract and/or introduction (that
are relevant for the evaluation) have not been reported. In addition to not
reporting outcomes, this would include reporting outcomes based on
composite score without individual outcome components or outcomes
reported using measurements, analysis methods or subsets of the data
(e.g. subscales) that were not pre-specified or reporting outcomes not pre-
specified, or that unplanned analyses were included that would appreciably
bias results.















++ There is evidence that variables, other than the exposure and outcome, did
not differ between groups during the course of the intervention in a way
that could bias results.
AND, in case randomisation is rated ‘probably low’/’definitely low’ RoB and
allocation concealment is rated ‘probably low’/’definitely low’ RoB or ‘not
reported’:
There is no evidence of differences in baseline characteristics.
OR
There is no information on both BUT no concern.
Opinion on the re-evaluation of pectin (E 440i) and amidated pectin (E 440ii) as food additives
in foods for infants below 16 weeks of age and follow-up of their re-evaluation as food
additives for uses in foods for all population groups
www.efsa.europa.eu/efsajournal 52 EFSA Journal 2021;19(1):6387
Question Rating Explanation for expert judgement
+ 1. There is evidence that variables, other than the exposure and outcome,
differed between groups during the course of the intervention.
AND it is deemed that these differences would not appreciably bias results
(no concern or adequately addressed by analysis).
AND, in case randomisation is rated ‘probably low’/’definitely low’ RoB and
allocation concealment is rated ‘probably low’/’definitely low’ RoB or ‘not
reported’:
There is evidence that reported variables differed between groups at baseline.
AND
It is deemed that these differences would not appreciably bias results (no
concern or adequately addressed by analysis).
OR
2. There is evidence that variables, other than the exposure and outcome, did
not differ between groups during the course of the intervention in a way that
could bias results.
AND, in case randomisation is rated ‘probably low’/’definitely low’ RoB and
allocation concealment is rated ‘probably low’/’definitely low’ RoB or ‘not
reported’:
There is evidence that reported variables differed between groups at baseline.
AND
It is deemed that these differences would not appreciably bias results (no
concern or adequately addressed by analysis).
OR
3. There is evidence that variables, other than the exposure and outcome,
differed between groups during the course of the intervention. AND it is
deemed that these differences would not appreciably bias results (no concern
or adequately addressed by analysis).
AND, in case randomisation is rated ‘probably low’/’definitely low’ RoB and
allocation concealment is rated ‘probably low’/’definitely low’ RoB or ‘not
reported’:
There is no evidence of differences in baseline characteristics.
OR
There is no information BUT no concern.
– There is no information on baseline characteristics AND/OR there is no




– There is evidence that variables, other than the exposure and outcome,
differed between groups during the course of the intervention.
AND
It is deemed that these differences appreciably biased results (there is
concern (e.g. not adequately addressed by analysis)) OR, in case
randomisation is rated ‘probably low’/’definitely low’ RoB and allocation
concealment is rated ‘probably low’/’definitely low’ RoB or ‘not reported’:
There is evidence that reported variables differed between groups at baseline.
AND
It is deemed that these differences appreciably biased results (there is concern
(e.g. not adequately addressed by analysis)).
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C.2. ‘Risk of bias summary’ for the clinical studies with pectins































































































































































































Dupont et al. (2015) ++ ++ ++ – – – ++ ++ 3
Vandenplas et al. (2016a) ++ ++ ++ – – – ++ ++ 3
Dupont et al. (2016a) – – – ++ – – ++ NA 3
Vandenplas et al. (2014) – – – + – – + NA 3
Rossetti et al. (2019) – – – – – – + NA 3
Dupont and Vandenplas
(2016b)
– – – + – – ++ NA 3
Moya et al. (2012) + + + – – + ++ + 3
Definitely low risk of bias (++), Probably low risk of bias (+), Probably high risk of bias (–), Definitely high risk of bias (), NA
not applicable.
C.3. ‘Risk of bias summary’ for the clinical studies with pectin-derived































































































































































































Fanaro et al. (2005) + –  +   – NA 3
Harvey et al. (2014) + –    – – NA 3
Burks et al. (2015) + –  –  – – – 3
Magne et al. (2008) ++ ++ ++ +  + ++ ++ 3
Piemontese et al. (2011) ++ ++ ++   + ++ ++ 3
Westerbeek et al. (2010) ++ ++ +   + ++ ++ 3
Definitely low risk of bias (++), Probably low risk of bias (+), Probably high risk of bias (–), Definitely high risk of bias (), NA
not applicable.
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Appendix D – Estimation of the fraction of the concentration of toxic
elements in pectin (E 440i) and amidated pectin (E 440ii) with respect to
the regulatory maximum levels in the final food product for which the
additive is used
The Panel estimated the fraction (%) of the concentration of the toxic elements lead and cadmium
in pectin (E 440i) and amidated pectin (E 440ii) with respect to the regulatory maximum levels in the
final product (formulae) as sold as laid down in Regulation (EC) No 1881/200623 considering:
• The current specification for lead and cadmium for pectin (E 440i) and amidated pectin
(E 440ii) according to Regulation (EU) No 231/2012, 5 and 1 mg/kg, respectively.
• The lowest technically achievable levels of lead and cadmium in commercial pectin products, 2
and 0.5 mg/kg, respectively, as proposed by one interested business operator (IBO;
documentation provided to EFSA n. 1), see also Section 3.5.
• The ‘modulated’ limits calculated by the Panel considering the analytical data as provided by
one IBO (documentation provided to EFSA n. 1), see also Section 3.5.
• The maximum permitted use level of pectins E 440i,ii in the final food of 10,000 mg/kg, the
maximum use level reported by industry (4,170 mg/kg) and the mean use level reported by
industry (3,466 mg/kg) for the uses in food for infants below 16 weeks of age, see Section 3.4
• The range of maximum levels (ML) for lead (0.01–0.05 mg/kg) and cadmium (0.005–0.02 mg/kg)
in formulae for infants as laid down in Regulation (EC) No 1881/2006.23
The results of the calculations can be found in Tables D.1 and D.2 for lead and Tables D.3 and D.4
for cadmium.
Table D.1: Estimation of the fraction of the concentration of lead in pectin (E 440i) and amidated
pectin (E 440ii) with respect to the regulatory maximum levels in the final product








MPL or Use level of






















5.0 10,000 0.0500 0.010 500.0
Current EU
specifications
5.0 4,170 0.0209 0.010 208.5
Current EU
specifications
5.0 3,466 0.0173 0.010 173.3
Proposal IBO 2.0 10,000 0.0200 0.010 200.0
Proposal IBO 2.0 4,170 0.0083 0.010 83.4
Proposal IBO 2.0 3,466 0.0069 0.010 69.3
Modulated* 0.3 10,000 0.0030 0.010 30.0
Modulated* 0.3 4,170 0.0013 0.010 12.5
Modulated* 0.3 3,466 0.0010 0.010 10.4
MPL: maximum permitted level.
*: Analytical values multiplied by a factor of 10 to account for representativeness, homogeneity and analytical measurement
uncertainty.
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Table D.2: Estimation of the fraction of the concentration of lead in pectin (E 440i) and amidated
pectin (E 440ii) with respect to the regulatory maximum levels in the final product









































5.0 10,000 80,000 0.4000 0.050 800.0
Proposal IBO 2.0 10,000 80,000 0.1600 0.050 320.0
Modulated** 0.3 10,000 80,000 0.0240 0.050 48.0
MPL: maximum permitted level.
*: Internal report on the harmonisation of dilution factors to be used in the assessment of dietary exposure, EFSA, 30 May 2018
available online https://zenodo.org/record/1256085#.X89vU9hKiUk.
**: Analytical values multiplied by a factor of 10 to account for representativeness, homogeneity and analytical measurement
uncertainty.
Table D.3: Estimation of the fraction of the concentration of cadmium in pectin (E 440i) and
amidated pectin (E 440ii) with respect to the regulatory maximum levels in the final
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1.0 10,000 0.010 0.005 200.0
Current EU
specifications
1.0 4,170 0.004 0.005 83.4
Current EU
specifications
1.0 3,466 0.003 0.005 69.3
Proposal IBO 0.5 10,000 0.005 0.005 100.0
Proposal IBO 0.5 4,170 0.002 0.005 41.7
Proposal IBO 0.5 3,466 0.002 0.005 34.7
Modulated* 0.1 10,000 0.001 0.005 20.0
Modulated* 0.1 4,170 0.000 0.005 8.3
Modulated* 0.1 3,466 0.000 0.005 6.9
MPL: maximum permitted level.
*: Analytical values multiplied by a factor of 10 to account for representativeness, homogeneity and analytical measurement
uncertainty.
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Considering the results of the above estimations and the fact that the food additive is not the only
potential source of toxic elements in the final food for infants, the Panel emphasises the need to
reduce the specification limit values for lead and cadmium in Regulation (EU) no 231/2012.
Table D.4: Estimation of the fraction of the concentration of cadmium in pectin (E 440i) and
amidated pectin (E 440ii) with respect to the regulatory maximum levels in the final











































1.0 10,000 80,000 0.080 0.020 400.0
Proposal IBO 0.5 10,000 80,000 0.040 0.020 200.0
Modulated** 0.1 10,000 80,000 0.008 0.020 40.0
MPL: maximum permitted level.
*: Internal report on the harmonisation of dilution factors to be used in the assessment of dietary exposure, EFSA, 30 May 2018
available online https://zenodo.org/record/1256085#.X89vU9hKiUk.
**: Analytical values multiplied by a factor of 10 to account for representativeness, homogeneity and analytical measurement
uncertainty.
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